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ABSTRACT 
 
The oncogenic PIM1 kinase has been implicated as a cofactor for the oncogene c-
MYC in prostate carcinogenesis. In this study, we show that coexpression of c-MYC and 
PIM1 is associated with high Gleason grade in prostate cancer. Using a tissue 
recombination model coupled with lentiviral-mediated gene transfer we show that Pim1 
is weakly oncogenic in naïve adult mouse prostatic epithelium. However, it cooperates 
dramatically with c-MYC to induce prostate cancer within 6 weeks. Importantly, c-MYC 
and Pim1 synergy is critically dependent on Pim1 kinase activity. c-MYC/Pim1-
expressing tumors showed increased phosphorylation of MYC on serine 62. Expression 
of a phosphomimetic c-MYC S62D mutant resulted in higher rates of proliferation 
compared to that of wild type c-MYC. However, c-MYC S62D did not result in tumors 
like c-MYC/Pim1 grafts, indicating that Pim1 cooperativity with c-MYC involves 
additional mechanisms other than enhancement of c-MYC activity by S62 
phosphorylation. In addition, c-MYC/Pim1-induced prostate carcinomas demonstrate 
evidence of neuroendocrine (NE) differentiation. Additional studies, including the 
identification of tumor cells co-expressing androgen receptor and NE cell markers 
synaptophysin and Ascl1 suggest that NE tumors arise from adenocarcinoma cells 
through transdifferentiation. These results directly demonstrate functional cooperativity 
between c-MYC and Pim1 in prostate tumorigenesis in vivo and support therapeutic 
strategies for targeting PIM1 in prostate cancer. 
Since Pim1 deficiency is well tolerated in vivo, it has been proposed that Pim1 
inhibition may offer an attractive option to impede prostate cancer progression. In the 
current study, we used small hairpin interfering RNA (shRNA) directed against Pim1 to 
xii 
 
determine the anti-tumor effects in prostate cancer cell lines. In mouse c-MYC/Pim1 
prostate tumor-derived cells and human prostate cancer cells, Pim1 knockdown markedly 
decreased cellular proliferation, survival, and tumorigenicity. Further studies indicate that 
in prostate cancer cells, Pim1 is required to maintain ERK/MAPK signaling pathway 
activation. Thus, Pim1 is necessary to maintain tumorigenicity, and may represent an 
efficient target for prostate cancer therapy.  
 
(Note: Human MYC and mouse Pim1 are cloned in lentiviral constructs and used for this 
study) 
 
 
 
1 
 
CHAPTER I 
 
INTRODUCTION 
 
Overview 
Prostate cancer is the most common cause of cancer in men and is a leading cause 
of cancer-related death among men.  More than 186,000 American men are diagnosed 
with prostate cancer each year. One out of every 6 men will get prostate cancer and one 
out of every 36 men will die of it (American Cancer Society, 2009). It has been shown 
that many features of prostate organogenesis are paralleled in the initiation and 
progression of prostate cancer. Therefore, understanding the development of the normal 
prostate should provide insights into tumor formation and progression, which will help in 
the identification of novel biomarkers and the development of efficient therapies to treat 
prostate cancer (Figure 1). Using in vivo tissue recombination models, we have examined 
the role of two oncogenes, Myc and Pim1 kinase and their synergism in prostate cancer 
development. We have also analyzed the functional role of Pim1 kinase in prostate 
tumorigenesis and its potential role as a therapeutic target. 
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Figure 1. The diagram of normal prostate and prostate cancer (Adapted from 
http://www.nlm.nih.gov/medlineplus/ency/images/ency/fullsize/18038.jpg). 
Prostate gland anatomy 
The prostate is a male accessory sex gland located in front of the rectum and 
below the urinary bladder, encircling the urethra (Aumuller, 1989) (Figure 2). The main 
function of the prostate is to produce components of the seminal fluid during ejaculation. 
The fluid secreted by the prostate gland is rich in proteins and ionic components 
including acid phosphatase, citric acid, prostate specific antigen (PSA), zinc and calcium 
(Aumuller, 1990). The alkalinity seminal fluid helps to neutralize the acidity of the 
vaginal tract and to support sperm survival (Aumuller, 1990). 
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. 
Figure 2. Anatomy of human prostate gland. The human prostate is a walnut shaped gland surrounding 
the urethra below the bladder (Adapted from http://www.cancer.gov). 
 
Prostate gland development 
The prostate develops from the urogenital sinus (UGS). The UGS is an 
ambisexual embryonic rudiment. The UGS consists of epithelium (UGE) and 
mesenchyme (UGM). UGS develops into the prostate, prostatic urethra and bulbourethral 
glands in males, the lower vagina and urethra in females, and into the bladder in both 
sexes (Cunha, 1987; Staack, 2003).  The UGS becomes the sexually dimorphic in 
response to androgens around 13.5 days post-coitum (dpc) in mice and 8 weeks in human 
fetus. Around 15.5 dpc in the mouse and 10 weeks in the human, the androgen responsive 
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UGM signals to the epithelium, inducing it to form epithelial buds. Then epithelial buds 
grow as solid cords into the surrounding mesenchyme. The solid cords canalize and 
progress into the branching network (Figure 3) (Kurzrock; 1999; Hayward, 2000; Staack, 
2003; Meeks, 2010).  In a reciprocal manner, prostate epithelial cells induce 
mesenchymal cells to differentiate into smooth muscle (Cunha, 2008). In humans, the 
gland enters a quiescent state after birth until the circulating androgen levels increase at 
puberty. After puberty, the gland begins to grow slowly and epithelium proliferates, 
resulting in the branching structures seen in the mature gland (Cunha, 1987). This growth 
phase continues until adulthood. At age of 45 to 50 years in humans, androgen levels 
decline and the prostate undergoes a period of involution. While man becomes older, 
benign prostatic hyperplasia commonly appears (Berry, 1984)  
  
Figure 3. Schematic representation of phases of prostate development. A, The prostate develops from 
the UGS in response to androgens. The UGS consists of both epithelium (green) and mesenchyme (blue). B, 
Androgens engage androgen receptor in the mesenchyme and induce epithelial budding. C, Epithelial buds 
elongate into solid cords of tissue that eventually canalize into ducts. D, Latter phases of prostate 
development include epithelial branching (Adapted from Meeks J, 2010.)  
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Prostate structure  
The mouse prostate comprises four pairs of lobes depending on the regions 
relative to the urethra: the anterioral (AP), ventral (VP), dorsal (DP) and lateral prostates 
(LP) (Figure 4). 
 
Figure 4. Schematic diagram of the adult mouse genitourinary tract (lateral view). The mouse prostate 
consists of four pairs of distinct lobes (Adapted from Sugimura, 1986). 
 
Lowsley identified several lobes of prostate in fetuses and newborns including a 
dorsal or posterior lobe, a median and two lateral lobes, and a ventral lobe (atrophied 
after birth). In the adult human, these lobes are fused and grow as a single lobe with 
distinct glandular regions (Lowsley, 1912). In McNeal's model, human prostate is divided 
into 4 glandular zones: the peripheral zone, transition zone, periurethral zone and central 
zone (McNeal, 1981) (Figure 5). Majority of prostate cancers arises in the peripheral 
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zone, while benign prostatic hyperplasia usually originates in transition zone, and a 
significant subset of prostate cancer (approximately 20%) also occurs in this zone 
(McNeal, 1981). 
 
Figure 5. McNeal’s model of the prostate 
1, Peripheral Zone; 2, Central Zone; 3, Transitional Zone; 4, Anterior Fibromuscular Zone. B= Bladder, U= 
Urethra, SV= Seminal Vesicle (adapted from Algaba, 1991) 
 
 
Although these are anatomic differences between the single lobed prostate in 
human and the multi-lobed prostate in mouse, the early histological events and the steroid 
hormones that drive prostate development are similar in both mice and humans during the 
prostate development (Meeks, 2010). Certain similarities in prostate anatomy, clinical 
and pathological features between the mouse and human prostate gland support the use of 
mouse models for studying the mechanisms of prostate cancer initiation and progression 
(Shappell, 2004). 
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Cell types in prostate gland 
Adult prostate epithelium consists of flattened basal cells, tall columnar luminal 
cells, and rare neuroendocrine (NE) cells (Figure 6). Luminal cells express AR, 
cytokeratin (CK) 8 and 18. Basal cells express p63, CK5 and CK14. Neuroendocrine 
cells express chromogranin A and synaptophysin. There are cells with intermediate 
phenotypes expressing a mixture of basal and luminal markers (CK5, CK8, CK14, CK18, 
and PSA) (Wang, 2001). The majority of stroma is smooth muscle. Fibroblasts, nerves, 
endothelial cells and vascular smooth muscle are also located in the stroma (Abate-Shen, 
2000; Wang, 2001) (Figure 6).  
 
 
Figure 6. Cell types within a human prostatic duct. Prostatic epithelial cells are composed of luminal, 
basal and rare neuroendocrine cells (Adapted from Abate-Shen, 2000). 
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Prostate cancer 
Prostate cancer diagnosis  
The primary method of screening for prostate cancer is serum analysis for 
prostate-specific antigen (PSA) (Catalona, 1991). PSA is a kallikrein serine protease that 
is secreted by prostate epithelial cells. PSA is released into blood due to morphological 
and pathological changes in the prostate. The major function of PSA is breakdown of 
semenogelins and fibronectin in coagulated semen, causing liquefaction of semen and 
facilitating fertilization (Lilja, 1985; 1987). Prostate cancer is associated with elevated 
level of serum PSA. However, elevation of PSA may indicate other prostatic diseases, 
such as benign prostatic hyperplasia (BPH) and inflammation of the prostate (prostatitis). 
A digital rectal examination (DRE) is also used to detect a problem in the prostate. An 
irregular or hard lump may indicate the presence of a tumor. Rectal examination also 
determines whether the tumor remains within the borders of the prostatic capsule or goes 
beyond it. However, enlargement of the prostate gland can be found in BPH patients. Not 
all of prostatic abnormalities can be found through the rectum. Both DRE and PSA test 
are also associated with high false-positive rates because they cannot tell whether the 
problem is cancer or a benign condition. They cannot predict progression of cancer, and 
may detect some indolent prostate cancer that would never have caused clinical problems. 
If an abnormality is found after PSA or DRE test, patients will be subjected to transrectal 
biopsy to diagnose prostate cancer. However, prostatic biopsies are associated with 
complications, including fever, pain, hematospermia/hematuria, positive urine cultures, 
and rarely sepsis (Rietbergen, 1997).  
Next, the pathologist examines biopsy samples under a microscope and gives a 
grade. One system of grading uses Gleason score. The most common pattern is given a 
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grade of 1 (like normal cells) to 5 (most abnormal). If there is a second most common 
pattern, the pathologist also gives it a grade of 1 to 5, and adds the two most common 
grades together to make the Gleason score (Gleason, 1974). Another system of grading 
prostate cancer uses the TNM system, which evaluates the size and invasive of the tumor 
(T1-T4), the extent of involved lymph nodes (N0 or 1), any metastasis (M0 or M1a-c) 
also takes into account cancer grade. These are often grouped into four stages (I–IV). 
(Denoix, 1944; 1950). 
Research has shown an increased risk of prostate cancer among men age over 65. 
The risk is higher if a family member had prostate cancer. The risk is also related to race, 
most common in African man, and lowest in Asians. Many other possible risk factors are 
under study. Researchers are also studying how to prevent prostate cancer. Certain 
chemo-preventive agents including, vitamin E, selenium, green tea extract seem to help 
in preventing prostate cancer (American Cancer Society). 
Prostate cancer treatment 
Prostate cancer can be treated by surgery, radiation therapy, hormone therapy, and 
chemotherapy. It has been reported that current prostate cancer treatments cause 
permanent side effects in men, such as erectile dysfunction and urinary incontinence 
(Harris, 2002; Litwin, 2000; Steineck, 2002). Prostate cancer cells depend on androgen 
receptor for growth and survival. The most common treatment for prostate cancer is 
hormone therapy (androgen ablation).  Although this treatment is effective initially, over 
time Castration-Resistant Prostate Cancer (CRPC) occurs, which is refractory to current 
therapeutic modalities. Therefore, one of major challenges in prostate cancer research is 
to find efficient therapeutic approaches for treatment of CRPC. Notably, some types of 
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prostate cancer are indolent and may need minimal or no treatment, other types are 
aggressive and can spread quickly (American Cancer Society). However, the accuracy of 
identifying indolent versus aggressive cancer was poor, which leads to over-diagnosis 
and over-treatment of prostate cancer. Because of these, controversy exists in regard to 
the value of screening, the most appropriate staging evaluation, and the optimal treatment 
of each stage of the disease (Garnick, 1993.) Therefore, one of major challenges in 
prostate cancer research is to design reliable screens for distinguishing indolent versus 
aggressive cancer, and to elucidate the factors that contribute to disease progression.  
Model of prostate cancer progression 
Human prostate tumorigenesis involves a series of genetic and epigenetic 
alterations that transform benign prostatic epithelial cells into precursor lesions prostatic 
intraepithelial neoplasia (PIN) with progression to invasive carcinoma and ultimately to 
metastastic disease.  The skeletal bone, lymph nodes and lung are major metastastic sites 
for prostate cancer (Shen, 2000) (Figure 7). During this process, many oncogenes such as 
Myc, Pim1, EZH2 and Egr1 are upregulated, while tumor suppressor genes such as 
Nkx3.1, p27, PTEN and p53 are downregulated (Abdulkadir, 2005). The long term goal 
for prostate cancer research is to identify genes and molecular pathways that are involved 
in the initiation and progression of prostate cancer. These studies will provide insight into 
new strategies for treatment and prevention of prostate cancer (Abate-Shen, 2000, Shen, 
2010). 
Neuroendocrine (NE) cells are a minor population in normal prostate epithelium. 
During the progression of prostate cancer, the number of NE cells in malignant lesions 
increases especially in advanced prostate tumor, which is correlated with its 
11 
 
tumorigenicity and hormone-refractory growth (Jiborn, 1998; Ito, 2001; Ismail, 2002; 
Hirano, 2004). The biological basis for androgen insensitivity is not well understood. 
Recent studies have focused on finding the determinants of metastasis and CRPC for 
identifying specific therapeutic targets.  
 
Figure 7.  Development of prostate cancer. Diagram showing transformation of normal prostate 
epithelium to PIN, invasive carcinoma and metastasis with the progression of disease (Adapted from 
Abate-Shen, 2000). 
 
Mouse models of prostate cancer 
Prostate cancer involves a series of genetic and epigenetic alterations that 
transform normal prostate epithelial cells into cancer cells. Therefore, the development of 
useful models is necessary for understanding of the molecular mechanisms of prostate 
cancer.  
Mice are used for modeling human cancer due to a relatively short gestation 
period and lifespan. Importantly, the essential functions of most mouse genes implicated 
in cancer are structurally homologous to those in humans. Furthermore, another 
advantage is that mice are susceptible to cancer as humans (Rangarajan, 2003). Indeed, 
mouse models have provided valuable information about exploring mechanisms of 
tumorigenesis and testing new therapies. 
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Genetically engineered mouse models 
Transgenic models 
 Androgen responsive prostate-specific promoters are used to drive the expression 
of transgenes in prostate epithelial cells. These include elements derived from rat 
probasin, rat C3 (1) prostate steroid binding protein, human prostate specific antigen 
(PSA), and mouse mammary tumor virus (MMTV) long terminal repeat (LTR). The 
probasin promoters (PB) are commonly used, which includes the minimal probasin 
promoter (Rennie, 1993), long probasin promoter (Yan, 1997) and minimal probasin 
promoter containing multiple androgen response regions (Kasper, 1994). Probasin and 
PSA promoters have been shown to essentially drive prostate-specific expression. 
ARR2PB promoter links two androgen response regions (ARRs) to the PB promoter, 
which drives high levels of transgene expression in transgenic mice (Ellwood-Yen, 2003; 
Zhang, 2000). MMTV LTR is responsive to androgen and several other steroid hormones. 
However, it has been shown that hormone sensitivity is not the only criterion for MMTV 
expression (Stewart, 1998). C3 (1) regulatory sequence induced gene expression can be 
found in other tissues in addition to the prostate (Green, 1998). 
TRAMP and LADY mice are two well characterized models of prostate cancer. 
They rapidly form invasive tumors with neuroendocrine features metastases (Greenberg, 
1995; Gingrich, 1996; Kaplan-Lefko, 2003; Kasper, 1998; Masumori, 2001). The 
TRAMP mice contain a minimal probasin promoter to drive the expression of SV40 large 
T and small t tumor antigens (Greenberg, 1995). SV40 large T antigen functions to 
inactivate the tumor suppressor p53 and retinoblastoma (Levine, 1990). Small t antigen 
blocks the function of protein phosphatase 2A (PP2A) and thus activates MAPK 
signaling pathway (Sontag, 1993). TRAMP mice develop high-grade prostate 
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intraepithelial neoplasia (HGPIN) within 12 weeks of age and adenocarcinoma and 
finally, metastatic spread to the lymph nodes, adrenal glands, lung and bone at 18 to 30 
weeks of age (Gingrich, 1999). LADY mice contain long probasin promoter to direct 
expression of only SV40 large T antigen (Kasper, 1998; Masumori, 2001). The LADY 
mice display the variable pattern of tumor formation depending on different sites of 
transgene integration, ranging from 12 weeks to over 20 weeks of age, following the 
development of poorly or undifferentiated carcinoma with NE differentiation (Kasper, 
1998; Masumori, 2001). 
Knockout models 
           Deletion of a gene of interest is another way to study gene functions. Due to 
embryonic lethality of some ablations, conditional knockout mice are made by using 
prostate specific promoter to drive Cre expression, such as Pb-Cre, Nkx3.1-Cre. The 
targeted gene was inactivated by Cre deletion of the floxed region and the expression of a 
truncated protein with loss of gene function. Some knockout models are shown in table1. 
However, these conditional knockout mice come from constitutively loss of function in 
early stages of prostate development. An inducible gene targeting system can overcome 
this limitation by inducing the expression of the gene of interest in adult prostate 
epithelium. Tamoxifen-inducible Cre driven PTEN null mice is an example of inducible 
mouse models (Luchman, 2008; Ratnacaram, 2008; Birbach, 2009). 
Some other engineered mouse models are shown in Table 1 (Adapted from Shen 
MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old 
challenges. Genes Dev. 2010 Sep 15; 24 (18):1967-2000). 
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Xenograft models  
Human prostate cancer cell lines or primary prostate cancer tissue can be injected 
subcutaneously or orthotopically into the severe combined immune deficiency (SCID) 
mice or nude mice (van Weerden, 2000). Xenograft models can monitor tumor 
progression under different experimental conditions and resemble in vivo situation of the 
original human cancer. In addition, some cancers are able to metastasize when injected 
into the organ of origin, providing a useful tool for evaluation of new therapies 
(Thalmann, 1994; Stephenson, 1992). However, this model has several limitations 
including impaired host immune system, low tumor take rate, incomplete tumor-stroma 
interactions, and heterogonous microenvironment in host-donor background. In addition, 
it is difficult to examine the multi-step cancer development since most xenografted 
tumors or tumor cell lines represent advanced tumor (Frese, 2007; Becher, 2006). There 
is a limited number of existing human prostate cancer cell lines and most of them lack 
wild type AR expression. Therefore, all of these limit their use to the study of prostate 
cancer initiation and progression.  
Tissue recombination models 
Engineered mouse models can be manipulated to investigate the functions of 
target genes in development, physiology and disease. However, it takes as long as 1-2 
years to make transgenic mice. Current engineered mouse models use androgen-
dependent promoters to drive expression of gene of interest.  They are not suitable for 
studying the effects of modulating androgen levels, since androgen deprivation will 
simultaneously change transgene expression. Tissue recombination is a reliable method 
of inducing prostate differentiation, which drives to important advances in our 
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understanding of prostate biology during development and disease. A tissue 
recombination model can be made by mixing epithelial cells and stromal cells in a 
collagen gel, and then grafting under kidney capsule of SCID or nude mice. In detail, 
rat urogenital sinus mesenchyme (UGM) is prepared from 18-day embryonic fetuses. In 
this stage, the interface of urogenital sinus epithelium (UGE) and UGM is relatively 
simple for separation. UGE or pieces of prostatic epithelium, or dissociated prostate 
epithelial cells are combined with UGM cells, and then are suspended in collagen. This 
tissue recombinant is subsequently grafted under the renal capsule of SCID mice. After a 
period of growth and development the host is sacrificed and the graft is removed (Figure 
8). Surgery to the renal capsule is slightly more difficult than subcutaneous grafting but 
the graft take is much more efficient. The function of the gene can be examined by the 
size and histology of the graft (Hayward, 1998; 2002). Tissue recombinants can 
recapitulate the pathologic features of the neoplastic prostate seen in transgenic mice 
(Ishii, 2005). It takes just a few days to regenerate prostatic branched network (Cunha, 
1983). In order to minimize cell culture artifacts and investigate the function of target 
genes in vivo, genes of interest can either be overexpressed or knocked down by 
retroviral or lentiviral transduction of dissociated primary prostate cells (Xin, 2003; 2005).  
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Figure 8. Diagram of tissue recombination approach. Fetal rat urogenital mesenchyme (UGM) cells are 
combined with adult prostate cells or pieces of tissue and collagen, and then implanted under the renal 
capsule to regenerate prostates. 
 
Compared to transgenic mice that contain the transgene in every cell or in organ-
specific subsets of cells under specific promoter, the tissue recombination model involves 
a small percentage of “transgenic” cells by retroviral or lentiviral infection surrounding 
normal uninfected cells within the microenvironment. These conditions more 
appropriately mimic those seen in the initiation of human cancer, where genetic 
alterations initially occur in only a few cells and not simultaneously in all cells of a given 
lineage. Tissue recombination model facilitates in situ study of gene specific effects in 
context of the prostate tissue. Another advantage is the elimination of culture-related 
artificial selection of cell populations because isolated epithelial or stromal cells can be 
directly used for tissue recombination. The generation of prostate cancer in the tissue 
recombination model not only defines a role for a specific transgene or combination in 
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prostate cancer, but also leads to establishment of many cell lines from cancerous and 
premalignant tissue grafts, which are subsequently used to further define the molecular 
basis of prostate cancer. This technique also allows to generate adult tissues of interest 
from transgenic or knockout mice that are embryonic lethal. 
Instead of implanting into subrenal capsule, cells or explants can also be put into 
pocket created under anterior lobe of the prostatic capsule, which is called orthotopic 
(prostate) xenograft (Figure 9) (Wang, 2005a). This technique is useful for studying 
metastatisis and provides insights to develop models to test new therapies (Wang, 2005b). 
 
Figure 9. Orthotopic xenografts of human prostate tissue in a SCID mouse. A, Whole mount showing 
the anterior prostate orthotopic graft in place. The  anterior prostate is seen in the “crook” of the seminal 
vesicle (SV).The graft (arrow) can be clearly seen nestled between the two main ducts of the anterior 
prostate (AP). B, Gentle microdissection reveals the graft which has clearly become extensively 
vascularized. C, Whole mount view of a sub-cutaneous graft beneath the skin of a SCID mouse (Adapted 
from Wang, 2005a). 
 
Prostate stem cell and cancer stem cell 
Normal prostate stem cell 
Stem cells are undifferentiated cells that are able to self-renew through 
asymmetric cell division and undergo multi-lineage differentiation (Becker, 1963; 
Siminovitch, 1963). Prostate stem cells (PSCs) are capable of giving rise to differentiated 
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basal, luminal and neuroendocrince cells during prostate development and regeneration 
(Taylor, 2010). 
The existence of prostate stem cells was initially implied by normal prostate 
regeneration after repeated cycles of androgen deprivation and restoration in rat (English, 
1987).  It is known that each lobe of mouse prostate contains three regions: distal, 
intermediate, and proximal regions. The proximal region of glands has been suggested to 
contain the mouse prostate stem cells (Figure 10) (Tsujimura, 2002; Burger, 2005). 
Tissue recombination approach also demonstrates the existence of prostate stem cells 
(Xin, 2003).  
 
Figure 10. Response of prostate epithelium to castration and androgen addition. Androgen withdrawal 
causes massive apoptosis in the prostate epithelium, leaving behind only castration-resistant cells. Upon 
addition of androgen, castration-resistant cells are capable of regenerating the gland. The cycle of 
involution and regeneration can be repeated in the rodent prostate almost indefinitely (Adapted from 
Goldstein, 2010).  
 
A lot of evidence supports the idea that PSCs reside in basal cells. For example, 
putative stem cell markers, Sca-1, CD44, CD49b, CD133, Bcl2, p63, CD117, Trop2, 
belong to prostatic basal markers (Liu, 1997; Signoretti, 2000; Collins, 2001; Richardson, 
2004; Xin, 2005; Lawson, 2007; Tsujimura, 2007; Goldstein, 2008; Yao, 2010). In 
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contrast, some evidence supports the concept that PSCs reside in luminal cells. It has 
been suggested that both basal and luminal epithelium contain putative stem cells as 
shown by the label-retaining methods (Tsujimura, 2002). It has been shown that p63 null 
cells have regenerative capacity of prostate in absence of basal cells (Kurita, 2004). A 
recent report shows that a small population of castration-resistant luminal cells 
expressing Nkx3.1 (CARNs) can regenerate prostate (Wang, 2009). Leong et al. isolated 
a single stem cell defined by Lin-Sca-1+CD133+CD44+CD117+ that can generate a 
prostate gland using tissue recombination method (Leong, 2008). Sca-1 and 
CD133 expression has been found in both stem and non-stem-cell types, including 
stromal and differentiated epithelial cells (Xin, 2005; Shmelkov, 2008). In addition, 
CD117 cannot be found either in basal layer or luminal layer, it remains to determine if 
Lin-Sca1+CD133+CD44+CD117+ cells have epithelial origin (Goldstein, 2010). These 
data suggest there may be multiple independent stem cell populations within the adult 
prostate, which respond to different stimuli.  
Cancer stem cell  
Cancer stem cells (CSCs) are cancer cells that have features of normal stem cells, 
specifically the ability to self-renew and differentiate into multiple cell types in a specific 
tumor. Such cells are tumorigenic and proposed to exist in tumors, which lead to cancer 
relapse and metastasis by giving rise to new tumors. It is possible that cancer stem cells 
come from transformation of normal stem cells or progenitor cells. It is also possible that 
cancer stem cells can be derived from transformed differentiated cells, resulting in 
dedifferentiation to acquire characteristics of stem cell. There might be some factors in 
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the microenvironment that cause the formation of cancer stem cells and initiate tumor 
formation (Figure 11) (Gupta, 2009; Maitland, 2008; Bjerkvig, 2005).  
 
Figure 11.  Potential cell origins of cancer stem cell. The diagram shows potential relationships between 
cancer stem cells and normal stem cells, progenitor cells, or differentiated cells. Mutations (lightning 
symbol) in a stem cell, progenitor cell or differentiated cell may give rise to a cancer stem cell that has self-
renewal potential and form new tumors. The microenvironment may be involved in the formation of a 
cancer stem cell (Adapted from Bjerkvig, 2005). 
 
At present, the origin of cancer stem cells is still not well understood. It is 
speculated that cancer stem cells may have luminal cell of origin since the luminal 
compartment expands and basal cells are lost during prostate cancer progression. It has 
been found that the putative prostate cancer stem cells exhibit basal cell features although 
prostate cancer is absence of basal cell (Collins, 2005). Transformed basal cells can 
generate prostate cancer with luminal phenotype (Wang, 2006; Lawson, 2007; 
Mulholland, 2009; Goldstein, 2008; 2010). Other studies have shown that prostate cancer 
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can be derived from transformed luminal cells (Ma, 2005; Korsten, 2009; Wang, 2009). 
Neuroendocrine cells may possibly represent a stem/progenitor cell population in prostate 
cancer (Palapattu, 2009). On the other hand, cancer stem cells may be derived from 
fusion between cancer cells and normal cells, stem cells and differentiated cells (Bjerkvig, 
2005).  In summary, different genetic alterations may target different cell types and 
induce different subtypes of cancer. Further study of cancer stem cells will provide the 
foundation for developing new methods in diagnosis, prevention and treatment of 
prostate cancer. 
c-MYC 
c-Myc gene was originally identified as cellular homologue of v-Myc which 
induced myelocytomatosis in birds (Vennström B, 1982; Sheiness D, 1979). Thereafter 
N-Myc and L-Myc were found to be amplified in neuroblastoma and small cell lung 
cancer, respectively (Kohl, 1983; Nau, 1985). These genes are homologous with same 
general topography. c-MYC is localized at chromosome 8q24.21, a region that is 
translocated in Burkitt's lymphoma (Dalla-Favera, 1982). The MYC genes have a short 
half-life of 20–30 min (Gregory, 2000). All Myc isoforms contain two independently 
functioning domains: a N-terminal transcriptional activation domain and a C-terminal 
DNA binding domain containing basic-helix-loop-helix-leucine zipper (bHLHZ) segment. 
Most biological functions of c-Myc require heterodimerization with its activation partner 
Max to the E-box sequence of c-Myc target genes (Blackwood, 1991). c-Myc also 
negatively regulates the transcription of genes which function to arrest the cell cycle, 
primarily through the c-Myc associated zinc finger protein, Miz1 (Schneider, 1997).  
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c-Myc (Myc, hereafter) is a multifunctional transcription factor that regulates cell 
cycle, growth and metabolism, differentiation, apoptosis, transformation, genomic 
instability, and angiogenesis (Figure 12). MYC is overexpressed in many types of tumors 
in human. Myc is required for embryonic stem (ES) cell pluripotency and reprogramming. 
Expression of Myc is generally high during early embryonic development (Cartwright, 
2005; Takahashi, 2006). Myc expression is low or undetectable in differentiated adult 
tissues, and is dramatically increased by growth factor-induced stimulation. Gardner, Lee 
& Dang summarized that “Myc expression persists into the cell cycle, but then returns to 
its basal level in resting cells. Abnormal or ectopic overexpression of Myc in primary 
cells activates a protective pathway through the induction of p19/p14ARF and a p53-
dependent cell death pathway. Hence, normal cells that overexpress Myc are eliminated 
from the host organism through apoptosis, thereby protecting the organism from lethal 
neoplastic changes” (Garden, 2002). Myc also inhibits cellular differentiation (Coppola, 
1986), shortens the cell cycle phases G1 and G2 (Karn, 1989), Myc has been implicated 
in inducing cyclin D1 and D2, cyclin E, CDK4, and Cdc25A, a phosphatase, which 
activates CDK2 and CDK4 (Bouchard, 1999; Coller, 2000; Hermeking, 2000). Myc has 
also been shown to reduce the level or inhibit the function of the CDK inhibitors p15, p21, 
and p27 (Gartel, 2003). A highly regulated cell cycle permits cells to repair DNA damage 
before replicating, thus protecting genomic integrity. Inappropriate regulated cell cycle 
results genomic instability. Myc overexpression has been reported to cause gene 
amplification, aneuploidy and polyploidy (Kuttler, 2006; Prochownik, 2008). Other 
studies suggest that Myc induces the production of reactive oxygen species (ROS), 
leading to DNA damage and genomic instability (Ray, 2006). Overexpression of MYC in 
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human cancers may contribute to enhanced tumor glycolysis, known as the Warburg 
effect (Figure 12) (Dang, 2010). 
 
Figure 12.  The Myc-Max heterodimer binds and activates E-box of target genes, and regulates 
downstream of target genes resulting in activation cell cycle regulation, apoptosis, or inhibition of cell 
adhesion (Adapted from Gardner, Lee & Dang, The Encyclopedia of Cancer, Second Edition, July 2002).  
 
In addition, Myc transcriptionally regulates a number of non-coding RNA 
transcripts including ribosomal RNAs, tRNAs and microRNAs (Cole, 2008). Myc also 
has a role in DNA replication, in which directly interacts with components of the 
replication machinery to positively regulate DNA synthesis. Overexpression of Myc 
induces inappropriate replication origin firing leading to replication stress and genomic 
instability evidenced by the activation of a DNA damage response (Dominguez-Sola, 
2007). 
Pim1 kinase 
The pim1 gene was initially identified as a proviral insertion site of the Moloney 
Murine Leukemia Virus (MoMuLV) (Cuypers, 1984). Pim1, Pim2 and Pim3 belong to 
25 
 
Pim family. They are conserved in vertebrates and show sequence and structural 
similarity (Mikkers, 2004). Pim family is constitutively active serine/threonine kinase 
that does not require posttranslational modification to be activated. Many cytokines, 
growth factors, hormones, and hypoxia can induce Pim1 expression (Dautry, 1988; Lilly, 
1992; Mui, 1996; Aho, 2005; Wang, 2001; Bachmann, 2005; Magnuson, 2010).  Pim1 
has a short half-life with 5 to 10 minutes in primary cells (Saris, 1991; Liang, 1996). The 
pim1 gene encodes two proteins of 33kD, and 44 kD using an alternative translation 
initiation at an upstream CUG codon (Saris, 1991). 33kDa Pim1 is primarily in the 
cytoplasm, whereas 44kDa Pim1 is primarily on plasma membrane (Xie, 2006).  
Pim1 structure 
Pim1 structure has been solved and demonstrated by several groups (Qian, 2005; 
Jacobs, 2005; Kumar, 2005). The binding site for ATP is located in a deep cavity formed 
by the N-terminal lobe containing anti-parallel β-sheets, and the C-terminal lobe 
containing α-helices. The active state of kinases is characterized by the presence of the 
conserved lysine-glutamate salt bridge (Lys67 and Glu89). The replacement of a lysine at 
position 67 by a methionine causes inactivation of the kinase (Figure 13). The Pim1 is 
post-transcriptionally regulated by eIF-4E (Hoover, 1997), stabilized by Hsp90 (Mizuno, 
2001) and degraded by PP2A (Losman, 2003).  
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Figure 13. Structural aspects of PIM1. A, Structural overview of the PIM1 crystal structure in complex 
with the nonhydrolysable ATP analogue AMPPNP. Regulatory elements (the phosphate binding (P)-loop, 
the magnesium binding motif DFG, the hinge region, the catalytic loop and the activation segment (A)-loop 
and the β-hairpin insert) are labelled and highlighted using different colors. B, Details of the interaction of 
the phosphate moieties of AMPPNP and Mg2+ with the D186FG motif, the conserved lysine (K67) and 
glutamate (E89) and the catalytic aspartate (D167). The enlarged region corresponds to part of the boxed 
area in A (Adapted from Brault, 2010). 
 
Pim1 activation and cytokine signaling 
Pim1 is induced by a large set of cytokines and is a downstream target for many 
cytokine-signaling pathways (Dautry, 1988; Lilly, 1992, Mui, 1996; Aho, 2005). 
STAT3/STAT5 can bind to the Pim1 promoter and upregulate Pim1 expression. Pim1 
itself can negatively regulate the Jak/STAT pathway by binding to SOCS1 and SOCS3, 
which are negative regulators of STAT signaling (Chen, 2002; Peltola, 2004). It is 
proposed that overexpression of Pim1 and other oncogenes, such as Myc, impairs this 
negative feedback, leading to hyperproliferation and tumor formation.  
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Pim1 and cell survival 
Pim1 is responsible for protecting cells from undergoing cellular apoptosis under 
adverse conditions (Moroy, 1993; Rahman, 2001). Pim1 phosphorylates Bad on serine 
112 to inactivate it and enhances Bcl-2 activity, thereby promoting cell survival (Aho, 
2004). Recent reports indicate that other Pim1 substrates are associated with cell survival. 
One of them is the proapototic transcription factor FOXO3a, which is inactivated by 
Pim1 (Morishita, 2008). Apoptosis signaling kinase 1 (ASK1) is also phosphorylated and 
inactivated by Pim1 (Gu, 2009). The other protein is MDM2, which is phosphorylated by 
Pim1, promotes cell survival (Hogan, 2008).  
Pim1 and cell cycle 
Pim1 promotes cell cycle G1/S progression by binding and phosphorylating the 
phosphatase Cdc25A (Mochizuk, 1999), cell cycle inhibitor p21Waf (Wang, 2002; Zhang, 
2007) and p27Kip1 (Morishita, 2008). Pim1 also phosphorylates Cdc25C associated kinase 
1(C-TAK1) and Cdc25C to promote transition from the G2 phase into mitosis 
(Bachmann, 2004). Nuclear mitotic apparatus (NuMA), responsible for the organization 
of the spindle apparatus in the M phase, is phosphorylated by Pim1 (Bhattacharya, 2002). 
Heterochromatin protein (HP) 1γ is identified as a Pim1 substrate (Koike, 2000). Pim1 
overexpression in human prostate cells leads to defects in mitotic spindle checkpoints, 
resulting in polyploidy and chromosome mis-segregation (Roh, 2003; 2005). 
Pim1 is a potential diagnostic biomarker  
Pim1 is up-regulated in human leukemia, lymphoma, prostate cancer, pancreatic 
cancer, gastric cancer, and head and neck squamous cell carcinoma (Amson, 1989; 
Dhanasekaran, 2001; Shah, 2008; Brault, 2010; Magnuson, 2010). The level of Pim1 
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expression correlates with the clinical outcome of prostate cancer patients despite the 
absence of Pim1 expression at some advanced metastatic tumor (Figure 14) 
(Dhanasekaran, 2001). Strong expression of Pim1 has been found to be associated with 
advanced prostate cancer. Detection of pim1 mRNA levels in prostate cancer 
demonstrates similar results with previous findings (Xu, 2005; He, 2009). Some PIN 
lesions display moderately strong Pim1 staining, which indicates Pim1 expression may be 
a potential early event in the development of prostate cancer (Valdman, 2004; Cibull, 
2006; van der Poel, 2010).   
 
Figure 14. Representative elements of a tissue microarray stained with anti-PIM1 antibody. a, 
Staining is absent or weak in benign prostate (top), but strong in the cytoplasm of localized prostate cancer 
(bottom). b, PIM1 expression is absent or weak in the secretory luminal cells of benign prostate glands 
(top), but strong in infiltrating prostate cancers (bottom) (Adapted from Dhanasekaran, 2001). 
Pim1 is a potential therapeutic biomarker  
Pim1 knockout mice are viable and fertile with subtle phenotypes in 
hematopoietic system and cytokine response (Laird, 1993; Domen, 1993). The feature of 
cell tolerated by Pim1 loss makes Pim1 as an attractive therapeutic target. In addition, 
Pim1 structure has been solved, which facilitates the development of Pim1 inhibitors. 
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Pim1 inhibitor quercetagetin is able to inhibit PIM1 activity in prostate cancer 
cells in a dose dependent fashion (Holder, 2007). SGI-1776 is another Pim1 inhibitor. 
Prostate cancer cells or B-cell chronic lymphocytic leukemia cells (CLL) treated by SGI-
1776 show a concentration dependent induction of apoptosis (Mumenthaler, 2009; Chen, 
2009). CLL cells treated with SGI-1776 show decrease phosphorylation of Myc on 
Serine 62 (Chen, 2009b). Currently, this compound is being used in human clinical trials 
for prostate cancer and lymphoma. In addition, it has been reported that Pim1 induces 
multi-drug resistance by increasing expression of two ABC transmembrane proteins - 
Pgp and BCRP (Xie, 2008; 2010). Therefore, inhibiting Pim1 kinase is a novel approach 
to abrogate Pgp and BCRP mediated drug resistance. Indeed, SGI-1776 
sensitizes prostate cancer cell to chemotherapy treatment (Mumenthal, 2009). In addition 
to chemical Pim1 inhibitors, anti-PIM1 monoclonal antibodys (mAbs) are reported to 
function as Pim1 inhibitors. It has been shown that anti-PIM1 mAbs lead to disrupt 
PIM1/Hsp90 complexes, reduce BAD phosphorylation at S112 and induce apoptosis (Hu, 
2009). All of these studies demonstrate that Pim1 can be a valuable therapeutic target. 
Pim1 and Myc synergism 
Pim1 shows strong synergism with Myc in lymphomagenesis. Pim1 induces 
lymphoma at a low frequency with a long latency (Cuypers, 1984; van Lohuizen, 1989). 
However, all mice overexpressing Myc and Pim1 died of leukemia in utero (Verbeek, 
1991). In human prostate cancer, both PIM1 and MYC are upregulated and suggest there 
is cooperation between them (Dhanasekaran, 2001; Ellwood-Yen, 2003). Pim1 is also 
overexpressed in Myc-driven prostate cancer mouse model (Ellwood-Yen, 2003). 
However, whether Pim1 and Myc do cooperate in prostate carcinogenesis has not been 
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demonstrated previously. The possible mechanisms of synergism between Myc and Pim1 
kinases have been reported according to in vitro studies: (1) Pim1 decreases PP2A 
activity, thereby decreasing dephosphorylated Myc S62, resulting in Myc stabilization 
(Chen, 2005). (2) Pim1 binds Myc, thereby increasing phosphorylation of Myc on serine 
62 and decreasing phosphorylation of Myc on threonine 58, resulting in stabilized Myc 
(Chen, 2005; Zhang, 2008). (3) Myc recruits Pim1 to the E boxes of the Myc target genes 
and phosphorylates histone 3 at serine 10, contributing to the activation of Myc target 
genes and cellular transformation (Zippo, 2007) (Figure 15). Although those mechanisms 
can partially explain the cooperation between Pim1 and Myc, the mechanisms of robust 
cooperation between Pim1 and Myc in vivo are still unclear. 
 
 
Figure 15. PIM1 is recruited to the E-box element by its interaction with MYC. The MYC–MAX–
PIM1 complex brings about the phosphorylation of H3S10, stimulates the binding of RNA polymerase II 
(Pol II) and contributes to the transcriptional activation of a subset of Myc target genes (Adapted from 
Zippo, 2007).    
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CHAPTER II 
 
PIM1 KINASE SYNERGIZES WITH C-MYC TO PROMOTE PROSTATE 
CANCER PROGRESSION 
 
 Introduction 
An important area in contemporary cancer research is defining the causative 
genetic alterations in tumors and their utility as molecular targets. In this regard, gene 
expression profiling studies have identified overexpression of the serine-threonine kinase 
PIM1 in a significant fraction of human prostate tumors where its expression is found to 
be tightly associated with that of MYC (Dhanasekaran, 2001; Valdman, 2004). Pim1 is 
also overexpressed in Myc-driven transgenic mouse prostate tumors (Ellwood-Yen, 
2003). Previous studies in mouse lymphoma models have shown that Pim1 and Myc 
synergize to promote lymphomagenesis (van Lohuizen, 1989; Verbeek, 1991; Möröy, 
1991).  
Pim1 is able to interact and phosphorylate several targets that are involved in cell 
cycle progression or apoptosis. Pim1 can inhibit apoptosis through interactions with the 
anti-apoptotic molecules, bcl-2 and Gfi-1 (Schmidt, 1998) or by inactivating 
phosphorylation of Bad at serine 112 (Aho, 2004). Substrates of Pim1 involved in cell 
cycle regulation include p21Cip1 (Wang, 2002), p27Kip1 (Morishita, 2008), NuMA 
(Bhattacharya, 2002), Cdc25A (Mochizuki, 1999), Cdc25c (Bachmann, 2006) and c-
TAK1 (Bachmann, 2004).  Pim1 overexpression increases the tumorigenicity of human 
prostate cancer cell lines (Ellwood-Yen, 2003; Chen, 2005; Bhattacharya, 2002; Roh, 
2005; 2008; Kim, 2010). Pim kinases may modulate phosphorylation of c-Myc on Ser62 
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through decreasing PP2A activity (Chen, 2005). Pim1 can increase Ser62 
phosphorylation while decrease Thr58 phosphorylation, thus increase c-Myc stability 
(Zhang, 2008). It has been showed that PIM1 binds MYC, modifys chromatin at at MYC 
binding sites, and activates MYC target genes (Zippo, 2007).  All of these observations 
suggested the possibility that Pim1 may cooperate with Myc in prostate tumorigenesis. 
However, whether Pim1 does indeed cooperate with Myc in prostate carcinogenesis in 
vivo has not been conclusively demonstrated. 
In this chapter, we first showed that coexpression of MYC and PIM1 in human 
prostate cancer samples is correlated with high tumor grade. Then we used a tissue 
recombination model to directly examine cooperativity between MYC and Pim1 in 
prostate tumorigenesis and the possible role of Pim1 kinase activity in this process. The 
results revealed a potent synergy between Pim1 and MYC in prostate cancer progression 
that is critically dependent on Pim1 kinase activity.  
 
Materials and Methods 
Lentiviral constructs 
Mouse Pim1, the kinase-dead mutant K67M was amplified using pMSCV-Pim1, 
pMSCV-K67M vector as templates (Roh, 2003). Human c-MYC was amplified using 
pHAMyc (kindly provided by Dr. L. Lee, Johns Hopkins University). Human c-MYC 
S62D mutant was cloned by mutating serine at position 62 (TCC) into aspartic acid 
(GAC) using PCR. Each above PCR product was cloned into the lentiviral transfer 
vector FM-1 biscistronically expressing YFP (kindly provided by Dr. Jeffrey Milbrandt, 
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Washington University) and was verified by restriction enzyme digestions and 
sequencing.  
Lentiviral preparation 
Lentivirus was produced by cotransfecting the transfer vector containing the gene 
of interest, the VSVG envelope glycoprotein, and the HIV-1 packaging vector Δ8.9 
(kindly provided by Dr. David Baltimore, Caltech) into 293FT cells (Invitrogen) using 
PEI reagent (Sigma). Virus supernatant was collected at 24, 48 and 72 hrs post-
transfection, and then was filtered through 0.45 µm filter.  Virus supernatant was 
concentrated by ultrafiltration using Centricon-70 following manufacturer's instruction 
(Millipore, UFC710008). Concentrated virus was stored at -80ºC. Viral titers were 
determined by infecting HT1080 cells with serial dilutions of virus and followed by flow 
cytometric quantification of YFP-positive cells after 3 days of infection.  In parallel, 
infected cells were visualized under a fluorescence microscope and cell lysates were 
prepared for Western blot. 
Tissue recombination 
All lobes of prostates were isolated from 6 week old C57BL/6 mice, minced and 
digested with collagenase, Trypsin, Dispase, DNase I, and passed through 100µm nylon 
mesh (BD Biosciences).  Dissociated prostate cells were infected with lentivirus at MOI 
50-100 in the presence of 8 µg/ml polybrene using the centrifugation method (Xin, 2003). 
Rat fetal urogenital mesenchyme (UGM) was prepared from 18-day embryos. Urogenital 
sinuses were dissected from fetuses and separated into epithelial and mesenchymal 
components by tryptic digestion as described previously (Hayward, 1998). Single UGM 
cells were then prepared by a 90-min digestion at 37°C with 187 units/ml collagenase. 1-
34 
 
2×105 cells were recombined with 2.5×105 rat urogenital mesenchyme (UGM) and 
suspended in rat tail collagen prepared as described (Hayward, 1998). The recombinants 
were incubated overnight and subsequently placed beneath the renal capsule of male 
SCID mice. Six or 12 weeks after grafting, the hosts were sacrificed. Animal experiments 
were performed according to protocols approved by the Institutional Animal Care and 
Use Committee at Vanderbilt University. 
Histology and immunohistochemistry 
Histological and immunohistochemical analyses were performed as described 
(Abdulkadir, 2001a; Abdulkadir, 2001b). Human tissue microarray was purchased from 
US Biomax, Inc. The following antibodies were used for immunohistochemical analysis: 
E-cadherin (BD Biosciences), smooth muscle actin (Sigma), synaptophysin (BD 
Biosciences), androgen receptor, c-MYC, FoxA2 and Nkx3.1 (all from Santa Cruz 
Biotechnology), p63 (Biocare Medical), cytokeratin 8 (Covance), Ki67 (Abcam), 
phospho histone H3 (Millipore), Ascl1 (BD Pharmingen), activated caspase 3 (Cell 
Signaling), chromogranin A, NSE (kindly provided by Dr. Robert Matusik, Vanderbilt 
University). For Ki67 and activated caspase3 quantitation, we counted at least 1000 cells 
per graft. For human prostate tumors samples, tissue arrays from Imgenex were stained 
by double immunofluorescence for MYC (1:15,000 with Tyramide Signal Amplification, 
Perkin-Elmer) and PIM1 (Santa Cruz Biotechnology, 1:50) as described (Kim, 2009). 
Coexpression was scored in samples where at least 50% of the cells coexpressed both 
antigens. Epithelial staining intensity was scored where > 5% of cells show staining on a 
4-point scale (0=negative, 1=weak, 2=intermediate, 3=strong) and samples were 
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categorized as either not overexpressing (scores 0, 1) or overexpressing (scores 2, 3) the 
antigen. Tissue histology was confirmed by H&E staining.  
Western blot analyses 
Western blot analyses were performed using the following antibodies: c-MYC, 
Pim1, AR (Santa Cruz Biotechnology, 1:500); β-actin, Cyclins D1, D2 , E (Santa Cruz 
Biotechnology,  1:1000); MYC phospho S62 (Abcam, 1:1000). 
Statistical analysis 
We compared groups by using student’s t-test or Chi-square test 
(http://www.quantpsy.org). Values were considered statistically significant at P < 0.05. 
Quantitative variables are expressed as means + SD while categorical variables are 
expressed as numbers (%).   
Results 
Co-expression of MYC and Pim1 in human prostate cancer  
To examine whether MYC and PIM1 proteins co-expressed in human prostate 
cancer, we employed double immunohistochemical staining of MYC and PIM1 in tissue 
microarrays (TMAs) from total prostatectomy specimens. In 91 specimens, MYC 
staining was observed in 52 (57%) cases and PIM1 staining was present in 58 (64%) 
tumor samples. There was considerable overlap between samples that express MYC and 
PIM1 (44.4%) (Figure 16A, B). In addition, among 28 samples with Gleason grade 4/5, 
17 (61%) tumor samples were MYC and PIM1 double positive. Coexpression of MYC 
and PIM1 was significantly correlated to higher Gleason grades (Figure 16C). These 
results are consistent with, and extend previous findings that MYC and PIM1 mRNA are 
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frequently coexpressed in human prostate tumors (Dhanasekaran, 2001; Ellwood-Yen, 
2003). 
 
Figure 16. Coexpression of MYC and PIM1 in human prostate tumors. A, Representative micrographs 
of human prostate tumor samples showing co-expression of c-MYC (green) and PIM1 (red) by double 
immunofluorescence staining. DAPI was used as a nuclear counter stain. B, Venn diagram showing overlap 
between samples positive for MYC and PIM1 overexpression. C, Gleason grade distribution of samples 
coexpressing MYC and PIM1 (MYC+PIM1+) compared to samples without coexpression of MYC and 
PIM1 (other). MYC+PIM1+ samples are associated with high Gleason grades. *P < 0.05.   
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Pim1 and MYC synergize to accelerate prostate cancer progression 
Lentiviral transfer vector expressing Pim1, or MYC was cloned into FM1 control 
vector, which bicistronically expresses yellow fluorescent protein (YFP) variant, Venus. 
To study whether Pim1 and Myc cooperation depends on kinase activity, we also cloned 
kinase-dead Pim1 mutant K67M. Lentivirus was produced, and all of concentrated virus 
titer was among 107- 108 infectious units (I.U.)/µl. The expression of target genes was 
determined using fluorescence microscopy and Western blot (Figure 17).  
 
Figure 17. Cloning lentiviral constructs and preparation of lentiviru expressing Pim1, or K67M, or 
MYC. A, Schematic of the bicistronic lentiviral vector FM-1 used to target transgene expression together 
with YFP/Venus. B, Microscopic detection of YFP fluorescence in lentiviral infected HT1080 cells. C, 
Western blot for detection of target protein expression in lentiviral infected HT1080 cells. 
 
To study the effects of MYC and Pim1 on naïve mouse prostate epithelium, we 
employed tissue recombination with lentiviral-mediated gene transfer (Xin, 2003). We 
infected dissociated prostate cells from 6-week old C57BL/6 mice with the control, Pim1, 
K67M or MYC-expressing lentiviruses singly or in combination (MYC/Pim1 or 
MYC/K67M). Cells were combined with rat UGM and grafted under the renal capsules 
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of SCID mice (Figure 18A). After six weeks, gross examination showed that the 
MYC/Pim1 grafts formed large hemorrhagic tumors while control, or Pim1, or K67M, or 
MYC and MYC/K67M grafts were small and did not differ significantly in their sizes 
(Figure 18B). Western blot confirmed appropriate transgene expression (Figure 18C). In 
MYC/Pim1 tumors, MYC and Pim1 proteins levels appear elevated, which may be due to 
the increased cellularity of tumors or other mechanisms such as increased protein stability. 
It is known that both Myc and Pim1 have short half-lives (Saris, 1991; Yeh, 2004) and 
Pim1 inhibits Myc degradation in a kinase-dependent manner (Zhang, 2008).  
 
 
Figure 18. Tissue recombination coupled with lentiviral-mediated gene transfer for expression of 
MYC and Pim1 in regenerated mouse prostate. A, Scheme used for prostate recombination. Primary 
mouse prostate epithelial cells were infected with the indicated lentiviruses and recombined with fetal rat 
urogenital mesenchyme to regenerate prostates.  B, Representative images of sub-renal capsule grafts 
(arrows) after 6 weeks. Scale bar, 5mm. C, Western blot analyses from 6-week graft tissue lysates with the 
indicated antibodies.  
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Histologically, all grafts from control (N=7), Pim1 (N=8) or K67M (N=8) group 
consisted of normal-looking prostatic glands (Figure 19). Two of Pim1 grafts showed 
very mild hyperplasia (data not shown), consistent with a weak oncogene. In contrast, all 
MYC (N=19) and MYC/K67M (N=11) grafts showed multiple foci of high-grade PIN 
(HGPIN), a putative precursor lesion for prostate carcinoma. These lesions are 
characterized by nuclear pleomorphism, prominent nucleoli, high mitotic activity, 
apoptotic figures and stromal hypercellularity. None of the MYC alone or MYC/K67M 
6-week grafts showed evidence of invasive cancer (Figure 19). Strikingly, MYC/Pim1 
grafts (N=17) consisted of prostate tumors growing as sheets of cells with notable rosette 
formation upon histological examination. The tumor cells had bubbly cytoplasm, 
vesicular nuclei, high nuclear: cytoplasmic ratios, large nuclei and prominent nucleoli 
(Figure 19). These tumors were also highly vascular. We observed 3 mice developed 
metastatic carcinoma and one of them died in the sixth week. These results indicate 
potent cooperation between MYC and Pim1 in prostate tumorigenesis which is critically 
dependent on Pim1 kinase activity. 
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Figure 19. MYC/Pim1 coexpression leads to high-grade prostate cancer within 6 weeks. H&E stained 
sections of 6-week grafts show normal-looking prostatic glands in control, Pim1 and K67M grafts. MYC 
and MYC/K67M samples show HGPIN lesions and hypercellular stroma. The MYC/Pim1 samples show 
high-grade tumor consistent with neuroendocrine carcinoma. Scale bar, 50 µm. Insets: Higher-
magnification images.  
 
Evidence of neuroendocrine differentiation in MYC/Pim1 tumors 
Normal prostatic epithelium consists of basal and luminal cells, as well as 
neuroendocrine (NE) cells. To characterize the cell types present in the regenerated grafts, 
we performed immunohistochemical analyses using a panel of cellular markers: androgen 
receptor (AR), E-cadherin, CK8, p63, smooth muscle actin (SMA), synaptophysin. 
Control, Pim1 and K67M, MYC or MYC/K67M grafts showed positive staining patterns 
for all of these markers (Figure 20). MYC/Pim1 tumors showed loss of AR, E-cadherin, 
p63, CK8, SMA and tumor suppressor Nkx3.1 (Figure 20, 22). These tumors 
ubiquitously expressed the NE marker synaptophysin (Figure 20). Further analysis 
showed that these tumors also expressed the neurogenic transcription factor Ascl1 (Hu, 
2004; Vias, 2008) and neuron-specific enolase (di Sant'Agnese, 1987) (Figure 21). 
However, MYC/Pim1 tumors did not express FoxA2, which is shown in some 
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neuroendocrine tumors (Mirosevich, 2006) (Figure 22). These results demonstrate that 
MYC/Pim1 co-expression leads to the development of high-grade cancer with 
characteristics of NE differentiation within 6 weeks.  
 
Figure 20. MYC/Pim1 co-expression shows evidence of neuroendocrine (NE) differentiation. 
Immunohistochemical analysis of 6-week grafts for expression of androgen receptor (AR), E-cadherin, p63, 
cytokeratin 8 (CK8), synaptophysin (SYN) and smooth muscle actin (SMA).  MYC/Pim1 tumors show low 
or loss of AR, E-cadherin, p63 and CK8 expression and strong expression of synaptophysin. HGPIN 
lesions in MYC group strongly express SMA in the hypercellular stroma. Note loss of SMA staining in the 
MYC/Pim1 tumors, consistent with their invasive nature. SMA positive cells surrounding blood vessels in 
MYC/Pim1 tumor served as internal positive controls. Scale bars, 50 µm. 
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Figure 21. Heterogeneous NSE and AsclI expression (brown) in MYC/Pim1 tumors. Control grafts 
show negative NSE and AsclI staining (Original magnification: 400×). 
 
Figure 22. Loss of expression of Nkx3.1 and FoxA2 in MYC/Pim1 tumors. Upper, immunochemical 
staining shows Nkx3.1 expression in control grafts, but loss of expression in MYC/Pim1 tumors (Original 
magnification: 400×). Lower, Staining for FoxA2 shows lack of expression in MYC/Pim1 tumors (Right). 
Left: positive control from liver metastasis of the LADY transgenic mice (kindly provided by Dr. Xiuping 
Yu and Dr. Robert Matusik, Vanderbilt University) shows nuclear expression (brown). (Original 
magnification: 200×). LADY transgenic mice develop prostate cancer due to SV40T antigen expression in 
the prostate (Masumori, 2001). 
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Notably, the MYC and MYC/K67M grafts were strongly positive for smooth 
muscle actin staining in the surrounding hypercellular stroma (Figure 20 and data not 
shown). Stromal reaction has been noted in association with HGPIN lesions in several 
mouse models of prostate cancer (Shappell, 2004). Since MYC expression was not found 
in the stromal part, the hypercellular stroma may result from an invasive phenotype 
(Figure 23). 
 
Figure 23. Immunohistochemical analysis of MYC expression in 6 week of MYC and MYC/Pim1 
grafts. Note nuclear MYC expression (brown) in HGPIN glands and tumor cells and absence of MYC 
expression in stroma (*) (Original magnification: 400×). 
 
MYC/Pim1 induced NE tumors arise from transdifferentiation of adenocarcinoma 
Neuroendocrine prostate cancer may arise directly from the transformation of rare 
neuroendocrine cells in the prostate or via the transdifferentiation of adenocarcinoma 
(Cindolo, 2007). If the neuroendocrine tumor arose from the transformation of 
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neuroendocrine cells, one would expect to see clusters of neuroendocrine cells in 
precursor HGPIN lesions. However, we did not observe clusters of synaptophysin 
positive cells in the HGPIN lesions from any of the MYC or MYC/Pim1 samples (Figure 
24 and data not shown). Therefore, the neuroendocrine tumors probably arose via the 
transdifferentiation of adenocarcinoma to a neuroendocrine phenotype.  
 
Figure 24. No clusters of NE cells in early lesions of MYC/Pim1 grafts. Left: A representative image of 
grafts showing that 4-week MYC/Pim1 grafts were much smaller than 6-week MYC/Pim1 grafts. Right: 
Representative H&E image of 4-week graft sections shows HGPIN and adenocarcinoma; that of 6-week 
graft sections shows high grade cancer (Original magnification: 100×).  Immunohitochemical staining 
shows that 4-week MYC/Pim1 grafts express AR but not express synaptophysin;  6-week MYC/Pim1 
grafts do not express AR but express synaptophysin (SYP) (Original magnification: 400×).  
 
Further evidence for this hypothesis was obtained by identification of cells that 
coexpress AR, MYC and the NE marker synaptophysin in MYC/Pim1 tumors (Figure 25). 
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These results are consistent with evidence of transdifferentiation of adenocarcinoma to 
neuroendocrine cancer (Wafa, 2007; Sauer, 2006; Hansel, 2009). 
 
Figure 25. Evidence that c-MYC/Pim1-induced neuroendocrine tumors arise by transdifferentiation. 
a-a”, MYC/Pim1 graft co-stained for androgen receptor (AR, red), synaptophysin (SYN, green) and 
nuclear stain DAPI (blue). b-b”, An adjacent section to that in ‘a’ stained for MYC (green), synaptophysin 
(SYN, red) and DAPI (blue). Arrows point to nest of tumor cells coexpressing AR, SYN and MYC.   c-c”, 
MYC/Pim1 graft co-stained for AR (red), Ascl1 (green) and DAPI (blue). Note coexpression of AR, Ascl1 
and MYC. d and d’, An adjacent section to that in ‘c’ stained for MYC (green), and DAPI (blue). Scale 
bars, 50 µm.   
Chronic Pim1 overexpression leads to the development of low grade PIN lesions 
 To examine the effects of chronic overexpression of Pim1, we allowed grafts to 
grow for 12 weeks. While grafts from the kinase-dead mutant K67M consisted of normal 
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glands, Pim1-expressing grafts showed focal epithelial hyperplasia and dysplasia 
consistent with low grade PIN (Figure 26).  
 
Figure 26. H&E sections show epithelial hyperplasia and LGPIN (arrow) in 12-week Pim1 grafts, 
while normal-looking prostate glands in K67M grafts.  Scale bars, 50 µm. 
 
Pim1 grafts showed a slight elevation of the Ki67-index compared to K67M grafts, 
but did not reach statistical significance. Both the Pim1 and K67M grafts showed low 
levels of apoptosis (Figure 27). Pim1 has been reported to interact with and 
phosphorylate several cell cycle and apoptotic molecules, including Cdc25A/C, C-TAK1, 
p21cip1, p27kip1 and Bad (Bachmann, 2005; Morishita, 2008).  Thus, Pim1 is expected to 
promote proliferation and inhibit apoptosis. The lack of a discernible phenotype in 6 
week-Pim1 grafts suggests that the homeostatic mechanisms operating in prostatic cells 
are able to buffer the effects of Pim1 overexpression. At 12 weeks, we speculate that a 
small reduction in the rate of apoptosis in Pim1 grafts coupled with a modest increase in 
47 
 
proliferation could account for accumulation of epithelial cells that manifests as 
hyperplasia. 
 
Figure 27. Proliferative (Ki67) and apoptotic (activated caspase 3) indices in 12-week grafts. Data 
shown as mean ± SD.*, P <0.05 relative to K67M or Pim1. **, P < 0.05 relative to all other groups. N=3.  
 
Chronic MYC overexpression results in adenocarcinoma and carcinoma with 
neuroendocrine differentiation   
Overexpression of Myc in prostate gland of transgenic mice demonstrated that the 
dosage of Myc expression is correlated to the rate of prostatic tumor progression 
(Ellwood-Yen, 2003; Zhang, 2000). In addition, based on the notion that Pim1 may 
cooperate with MYC by amplifying MYC activity, we speculated that chronic expression 
of MYC alone may result in tumors that resemble 6-week MYC/Pim1 tumors (Williams, 
2005). Actually, two different sizes of MYC grafts were observed 12 weeks postgrafting 
(Figure 28A).  Histologically, smaller size of MYC grafts contained HGPIN lesions, 
while larger grafts were comprised of high grade adenocarcinoma consistent with 
neuroendocrine differentiation (Figure 28B). Indeed, grafts with MYC overexpression for 
12 weeks produced synaptophysin-positive neuroendocrine tumors and invasive 
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adenocarcinoma with focal synaptophysin-positive cells (Figure 29), which further 
illustrates that neuroendocrine phenotype arises via the transdifferentiation of 
adenocarcinoma. 
 
Figure 28. The size and histology of twelve-week MYC grafts.  A, MYC grafts show two different sizes. 
MYC (I) is much smaller than MYC (II). B, H&E staining shows two types of lesions: MYC grafts (I) 
display HGPIN with invasive adenocarcinoma (arrows), whereas MYC grafts (II) consist of high-grade 
tumor. N=2 each. Scale bars, 50μm. 
 
Figure 29. Immunohistochemical staining for synaptophysin (SYN) in 12 week-MYC grafts shows 
isolated focal expression (arrows) in MYC (I) adenocarcinoma and strong expression in MYC (II) 
neuroendocrine tumor. Scale bars, 50μm. 
 
The 12-week MYC neuroendocrine tumors expressed low levels of AR using 
immunohistochemistry (Figure 30) and Western blot analysis (Figure 31)  
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Figure 30. Immunohistochemical staining of androgen receptor in 12 -week grafts. Note uniform 
nuclear expression (brown) in glands from K67M and Pim1 grafts and examples of heterogeneous or nearly 
total loss of expression in two different MYC tumors (Original magnification: 400×). 
 
 Interestingly, Western blot analysis of the 12-week grafts showed that slightly 
increased endogenous Pim1 in synaptophysin-positive MYC tumors (Figure 31), 
suggesting that with progression, MYC tumors select for Pim1 overexpression, or Pim1 
may be induced by neuroendocrine tumor secreted factors. These results are consistent 
with previous observations of Pim1 mRNA overexpression in probasin-Myc transgenic 
tumors although those tumors were not reported to express markers of NE differentiation 
(Ellwood-Yen, 2003).  
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Figure 31. Western blot shows that Pim1, MYC and AR expression in 12-week grafts.  Note increased 
Pim1 and reduced AR expression in MYC (II) sample. 
 
Analysis of 12-week MYC grafts showed levels of proliferation and apoptosis 
consistent with tumor grade, with the neuroendocrine tumors showing the highest rates of 
proliferation and apoptosis (Figure 27). 
Pim1 may inhibit MYC-induced apoptosis 
Myc is known to induce proliferation as well as apoptosis. The Pim1 kinase 
inhibits apoptosis via interactions with the anti-apoptotic molecules, Bcl-2 and Gfi-1 
(Schmidt, 1998) or by phosphorylation and inactivation of the pro-apoptotic proteins, 
Bad (Aho, 2004), FOXO3a (Morishita, 2008) and ASK1 (Gu, 2009). On the other hand, 
Pim1 has also been reported to promote Myc mediated apoptosis in serum-deprived Rat-1 
fibroblasts (Mochizuki, 1999). We speculated that Pim1 cooperates with MYC by 
inhibiting the apoptotic effect of Myc. Therefore, we analyzed proliferation and apoptosis 
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using immunohistochemical staining. Notably, the rates of proliferation (Ki-67 index) 
and apoptosis (activated caspase 3 index) were similarly low in the 6-week control, Pim1 
and K67M grafts, consistent with the absence of histological alterations in these tissues. 
However, there were significant increases in proliferation and apoptosis in the MYC 
grafts and similar increases were noted in the MYC/K67M group. The Ki67-index was 
dramatically increased in the MYC/Pim1 tumors consistent with the nature of high-grade 
tumors. The apoptotic index was also elevated indicating high turnover of the tumor cells 
(Fig. 32A, B). The increased apoptosis in the MYC/Pim1 tumors may be due to the 
markedly elevated rates of proliferation. Although there were many more cells 
undergoing proliferation than apoptosis, the net effect was increased tumor growth.  
 
Figure 32. Increased cellular proliferation and apoptosis in MYC/Pim1 tumors. The increased 
apoptosis may be due to the dramatically increased proliferation in the MYC/Pim1 tumors. A, Ki67 
proliferative index in graft tissues. B, Apoptotic index in graft tissues determined by staining for activated 
caspase 3. Data shown as mean ± SD, N=3. *, P <0.05 relative to control. **, P < 0.05 relative to all 
samples. 
 
It is speculated that proliferative and apoptotic rates were not comparable between 
PIN (MYC grafts) and cancer (MYC/Pim1 grafts). Therefore, proliferative and apoptotic 
rates were analyzed between 6-week MYC/Pim1 tumors and 12-week MYC (II) tumors. 
The result showed that MYC (II) tumors had higher apoptotic rates than MYC/Pim1 
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tumors. Furthermore, apoptosis normalized to proliferation was higher in MYC (II) tumor 
than MYC/Pim1 tumor (Figure 33). 
 
 
Figure 33. Pim1 suppresses MYC-induced apoptosis. Left: 12-week MYC (II) tumors show higher 
apoptotic rates comparing to MYC/Pim1 tumors. Data shown as mean ± SD, N=2-3. *, P <0.05. Right: 
Apoptotic rate normalized to proliferative rate is higher in MYC (II) tumors than MYC/Pim1 tumors. Data 
shown as average ratio of apoptosis to proliferation. N=2-3. 
 
Pim1 may increase MYC target gene expression and MYC protein stability 
It has been reported that PIM1 may enhance MYC stability and activity by 
increasing the phosphorylation of MYC on serine 62 (MYCS62P) (Chen, 2005; Zhang, 
2008). Other studies have shown that PIM1 and MYC binding induces phosphorylation 
of histone H3 on serine 10 and facilitates transcriptional activation of MYC target genes 
(Zippo, 2007). Based on these studies, it is expected that MYC activity will be enhanced 
in MYC/Pim1-expressing tumors. Consistent with this notion, we found that relative 
levels of MYC and MYC targets, cyclin D1, cyclin D2 and cyclin E, were elevated in 
MYC/Pim1 tissues comparing those in MYC or MYC/K67M grafts (Figure 34A, B). 
Furthermore, phosphorylation of MYC on S62 normalized to total MYC protein level 
was higher in MYC/Pim1 tumors than MYC or MYC/K67M grafts (Figure 34C). 
0
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Increased MYC target gene expression and MYC protein stability may due to the 
cooperation between Pim1 and MYC, but also may due to indirect gene activation as 
consequences of tumorigenesis.  
 
Figure 34. Western blot for detecting Cyclin D1, Cyclin D2, Cyclin E and phosphorylation of MYC 
on S62 in graft lysates.  A, Western blot for the indicated proteins in graft lysates. B, Quantitation of 
Cyclins D1, D2 and E levels from “C” normalized to actin level.  C, Upper panel: Western blot for serine-
62 phosphorylated MYC (MYCS62P) and total MYC. Lower panel: Quantitation of Western blot data. 
Data shown as mean ± SD, N=2. 
 
To directly assess the contribution of MYC phosphorylation on serine-62 to 
tumorigenic activity in vivo, we used the same approach to generate grafts expressing 
MYC phosphomimetic mutant MYC S62D (serine-to-aspartic acid). The size and 
histology of grafts revealed no significant difference between MYC and MYCS62D 
grafts (n=4) (Figure 35A, B). Like the MYC grafts, MYC S62D grafts showed HGPIN 
with no evidence of invasive cancer as confirmed by SMA staining (Figure 35B). To 
precisely assess proliferative rates only in MYC-expressing cells, we co-stained the graft 
sections with phospho-histone H3 (a mitotic marker) and MYC. This analysis revealed a 
higher mitotic index in the MYC S62D grafts than MYC grafts (Figure 35C). Although 
MYC S62D phosphorylation has some positive effects on MYC tumorigenicity, it does 
not account for the bulk of the cooperativity between MYC and Pim1. The functions of 
Pim1 on MYC transforming activity needs to be further explored. 
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Figure 35. The phenotype of phosphomimetic mutant MYCS62D is similar to that of MYC rather 
than that of MYC/Pim1 grafts. A, The size of six-week grafts expressing the phosphomimetic mutant 
MYCS62D is similar to that of wild type MYC grafts, and much smaller than the size of MYC/Pim1 grafts. 
B, H&E and SMA staining show that MYCS62D is similar to wild type MYC grafts. Scale bars, 50 µm. C, 
Upper panel: representative image of histone H3 (red) and MYC-expressing cells (green). Lower panel: 
quantization of proliferation. Higher mitotic index (% phospho-histone H3 positive MYC-expressing cells) 
in grafts expressing the MYCS62D mutant (n=4) compared to those expressing wild type MYC (n=5). Data 
shown as mean ± SD. * P < 0.05. 
 
Discussion 
In humans, PIM1 and MYC levels are upregulated, which suggests they cooperate 
in prostate tumorigenesis. In this study, we found that a significant percentage of the 
human prostate cancer samples exhibited concurrent overexpression of MYC and PIM1, 
which is associated with high Gleason grades. Therefore, we examined the effects of 
MYC and Pim1 overexpression in prostate carcinogenesis using a tissue recombination 
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model. Our study has provided several insights. We demonstrated that Pim1 by itself is 
weakly oncogenic, and Pim1 synergizes dramatically with MYC to promote the 
development of advanced prostate carcinoma. These results are consistent with previous 
reports in mouse lymphoma models (Van Lohuizen, 1989; Verbeek, 1991). Our results 
also demonstrated a strict requirement for Pim1 kinase activity for both its oncogenic 
activity and its ability to synergize with MYC. The precise mechanism by which MYC 
and PIM1 cooperate in prostate carcinogenesis needs to be further explored. 
Tumors derived from the co-expression of MYC and Pim1 show evidence of 
neuroendocrine differentiation. Pure neuroendocrine or small cell carcinoma of the 
prostate is rare, and has a poor prognosis. However, partial neuroendocrine differentiation 
in prostate cancer, defined as expression of one or more neuroendocrine markers such as 
Chromogranin A, synaptophysin, Neuron specific enolase, L-Dopa carboxylase, is more 
common and is associated with a poor prognosis (Yuan, 2007; Wafa, 2007; Sauer, 2006; 
Hansel, 2009). There is also extensive literature on the transdifferentiation of prostate 
adenocarcinoma to neuroendocrine phenotype. For example, LNCaP human prostate 
carcinoma cells can be induced to transdifferentiate to NE-like cells by androgen 
depletion, interleukin-6 treatment or genistein treatment (Zhang, 2003; Pinski, 2006; 
Deeble, 2001; Kim, 2002). In addition, several observations support the notion that the 
MYC/Pim1 tumors arise from transdifferentiation of adenocarcinoma cells to acquire 
neuroendocrine features rather than from the transformation of the rare neuroendocrine 
cell type in the prostate. First, prostate tissue recombinants are derived from adult mouse 
prostate cells by prostate regeneration, and if rare neuroendocrine cells were transformed 
by oncogene expression, one would expect to see clusters of transformed neuroendocrine 
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cells in early lesions. However, we have never observed clusters of transformed 
neuroendocrine cells in precursor PIN lesions (Figure 24 and data not shown). This is in 
contrast to the situation in which neuroendocrine cells are transformed, such as targeted 
expression of T antigen in the Cr2-TAg model. In Cr2-TAg mice, transformed 
neuroendocrine cell clusters are readily identified in PIN lesions (Garabedian, 1998; 
Abdulkadir, 2001b). Secondly, we were able to identify cells coexpressing both AR and 
synaptophysin, consistent with transdifferentiation of adenocarcinoma cells to 
neuroendocrine cancer, similar to recent observations in some human prostate tumors 
(Wafa, 2007) as well as in TRAMP mice (Kaplan-Lefko, 2003). Mouse prostate-specific 
deletion of Trp53 and Rb induces neuroendocrine tumors in prostate and up-regulation of 
Pim1 and L-Myc (Zhou, 2006). Tumors from this model were also found to co-express 
synpatophysin and androgen receptor and to up-regulate the pro-neural transcription 
factors Ascl1 and Hes6. Interestingly, the expression of pro-neural transcription factors 
was useful in segregating metastatic form localized prostate cancer (Vias, 2008). 
Our findings clearly show that Pim1 kinase activity is important for the synergy 
between Pim1 and MYC in prostate carcinogenesis. The Pim1 has recently garnered 
interest as a possible molecular target in multiple cancers including lymphomas and 
prostate cancer. Mice deficient in Pim1 or all Pim kinases (Pim1/Pim2/Pim3) showed a 
very mild phenotype, suggesting that therapeutic inhibition of Pim1 may be well tolerated 
in vivo. Therefore, MYC/Pim1 tissue recombination model may be appropriate for testing 
therapeutic modalities aimed at inhibiting Pim1 kinase activity as it avoids both the 
drawbacks of xenograft models that use advanced cancer cell lines as well as the 
cost/time constraints that hamper most transgenic models. 
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CHAPTER III 
 
PIM1 IS REQUIRED TO MAINTAIN THE TUMORIGENIC POTENTIAL OF 
PROSTATE CARCINOMA CELLS 
 
 Introduction 
Prostate cancer is the most common malignancy in men and the second leading 
cause of cancer-related death in the Western world. Advanced prostate cancer is 
typically androgen-insensitive and resists conventional chemotherapy, hormone therapy 
and radiation therapy. Neuroendocrine differentiation has been shown to correlate with 
hormone deprivation therapy and tumor progression (Abrahamsson, 1999; Hirano, 2004; 
Vashchenko, 2005; Bonkhoff, 2005).  
Pim1 has been implicated in leukemias, lymphoma and some solid tumors such as 
prostate cancer, pancreatic cancer, and oral cancer (Shah, 2008). Pim1 is a conserved 
active serine/threonine kinase (Reeves, 1990; Saris, 1991). Transgenic mice 
overexpressing Pim1 delayed lymphoma at a low frequency (Cuypers, 1984; van 
Lohuizen, 1989). However, all mice overexpressing Myc and Pim1 died of lymphomas in 
utero (Verbeek, 1991). Our recent study showed that Pim1 potently synergizes with MYC 
to accelerate prostate cancer progression (Chapter II; Wang, 2010). The mechanism of 
cooperation between Pim1 and c-Myc has not been clearly established. Pim1 has been 
reported to promote tumorigenicity by increasing Myc expression or stability (Chen, 
2005; Zhang, 2008). Pim1 also has been shown enhancing the transcription of Myc target 
genes (Zippo, 2007; Kim, 2010). The phospomimetic mutant of Myc on Ser329 has 
comparable tumorigenisity to coexpression of Pim kinases and Myc in vitro (Zhang, 
58 
 
2008). However, in our tissue recombination model, the phosphomimetic MYC-S62D 
mutant did not form aggressive tumors as MYC/Pim1 grafts. It is unknown whether other 
MYC mutation sites that stabilize MYC, such as MYC-S329D, can induce tumor similar 
as co-expression of MYC and Pim1 in vivo. We speculated that other mechanisms may 
be involved in Pim1 and MYC synergism in prostate cancer addition to increasing MYC-
transcriptional activity by Pim1. On the other hand, in tissue recombination model, Pim1 
overexpression results in hyperplasia with focal low grade PIN lesions after 12 weeks, 
while MYC and Pim1 co-expression leads to the development of aggressive prostate 
cancer within 6 weeks suggesting that Pim1 is a weak oncogene, and strongly cooperates 
with Myc. Tumors that co-express MYC and Pim1 showed signs of neuroendocrine 
differentiation, which is observed in advanced stage of human prostate cancer and is 
associated with poor prognosis (Abrahamsson, 1999; Miyoshi, 2001; Hirano, 2004; 
Vashchenko, 2005; Bonkhoff, 2005, Taplin me, 2005; Berruti, 2005; Mcwilliam; 1997; 
Kamiya, 2008). It is needed to be explored whether inactivation of Pim1 in advanced 
tumor is sufficient to induce tumor regression and prevent tumor formation. 
Pim1 overexpression is observed in more than 50% of human prostate cancer, 
which is correlated with the high Gleason score.  Pim1 is also proposed to be a diagnostic 
and prognostic factor in prostate cancer (Dhanasekaran, 2001; Valdman, 2004; Cibull, 
2006; Xu, 2005; He, 2009). In addition, Pim1 appears to be essential for tumor 
progression and maintenance. Several therapeutic agents have been developed to inhibit 
Pim1 kinase activity, for example, Pim1 inhibitor Quercetagetin (Holder, 2007); SMI-4a 
(Lin, 2009); SGI-1776 (Chen, 2009b; Mumenthale, 2009), anti-PIM1 monoclonal 
antibody (Hu, 2009). Pim1 is constitutively active and its protein levels correlated with 
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kinase activity Therefore, decrease of PIM1 levels indicates decreased kinase activity, 
thereby inhibiting tumorigenicity (Qian, 2005).  RNA interference can specifically 
silence gene expression, so it can be used for blocking the expression of oncogenes in 
cancer cells. To determine whether Pim1 expression is necessary to maintain the 
malignant phenotype and its potential therapeutic role, we used short hairpin RNA 
(shRNA) directed against expression of Pim1 to determine the effects of decreasing the 
levels of Pim1 expression in prostate cancer cell lines. We found that lentivirus-mediated 
shRNA against Pim1 markedly decreased Pim1 gene expression, and inhibited cellular 
proliferation and survival of prostate cancer cells. Pim1 knockdown also reduced 
tumorigenic potential of prostate cancer cells.  In addition, phosphoralytion of ERK1/2 
was reduced upon Pim1 knockdown. These results indicated that Pim1 is required for 
tumorigenic maintenance, even in the presence of high MYC level. Targeting Pim1 
would be effective for the treatment of prostate cancer, even for advanced stages of 
cancer. 
 
Materials and Methods 
Cell lines and constructs 
 
DU145 cells were cultured in RPMI medium with 10% fetal bovine serum (FBS). 
MPT cells were isolated from MYC/Pim1 tumors. Briefly, MYC/Pim1 tumors were minced 
and digested into single cells using collagenase, then plated on collagen-coated dish with 
DMEM/F12/10% FBS medium. After confluences the cells were split into regular cell 
culture dishes.  
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Stable knockdown of Pim1with shRNA  
Lentiviral pGIPZ shRNAmir against mouse Pim1 (V2LMM_46214) and the 
sequence-scrambled, non-silencing-GIPZ lentiviral shRNAmir control (RHS4346) were 
provided by Vanderbilt Functional Genomics shared resource (Open Biosystems). 
Lentiviral pLKO.1 shRNA targeting human, mouse, rat Pim1 (RHS3979-9631245) and 
control empty vector were obtained from Open Biosystems. Lentivirus was prepared as 
described in Chapter II. MPT or DU145 cells were infected by virus in the presence of 
8μg/ml polybrene. Puromycin was added to select stably transduced cells 2 days after 
infection. 
Western blot analysis 
Cells were washed with PBS, and then RIPA buffer with protease inhibitors was 
added. Cells were harvested with cell scraper, briefly sonicated and spun down. Lystate 
was run on SDS-PAGE, transferred to PDVF membranes. Membranes were blot with the 
following antibodies: c-MYC, Pim1, AR and Actin (Santa Cruz Biotechnology); p44/42 
MAPK (Erk1/2), phospho-p44/42 MAPK (Thr202/Tyr204) (Cell signaling); β-actin (Santa 
Cruz Biotechnology); β-tubulin (Sigma). 
Proliferation assay 
For cell growth curve, MPT Cells were seeded at 20,000 cells per well in a six-
well plate. Viable cells determined by trypan blue-excluding ability were counted using a 
hemocytometer. For MTS assay, cells were quarterly plated on 96-well plate. 3 days later, 
CellTiter 96® Aqueous One Solution (Promega) was added to each well and absorbance 
was read at 490 nm in a plate reader according manufacture’s instruction. 
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Active caspase 3 staining 
Cells were plated on glass coverslips. Cells were fixed in 2% paraformaldehyde 
for 10 minutes followed by permeabilization in 1% Triton X-100 for 10 minutes. After 
washing in PBS, cells were blocked in 10% goat serum, stained with activated caspase-3 
(Cell Signal) at 1:500. Coverslips were mounted on slides using Vectashield mounting 
medium (Vector Laboratories). 1000 cells were counted per cover slip. 
Colony formation assay  
5,000 of MPT cells were plated in 10 cm dishes. Triplicate experiments were 
performed for each cell line. The medium was changed every 3-4 days. After 10-14 days, 
the cells were fixed and stained with crystal violet.  
Soft agar assay 
A 2 ml of 0.6% agar in RPMI-10% FBS was placed into each well of 6 well plate. 
After agar solidified, 2 ml of 0.3% top agarose in RPMI-10% FBS containing 10,000 cells 
was added to each well. The cells were fed every 3-4 days with RPMI/10% FBS. The 
plates were incubated for 2 weeks. The colonies that are larger than 100μm were counted. 
Each soft agar assay was performed in triplicate.  
In vivo tumorigenicity assay 
1×105 control MPT or Pim1 knockdown cells (shControl#1 and shPim1#1) were 
mixed with 15μl of Matrigel (Becton Dickinson Labware) and injected subcutaneously in 
both flanks of 8-week-old male athymic nude mice (BALB/c strain; Harlan Sprague 
Dawley).  Grafts were measured weekly. All mice were sacrificed by 12 weeks after 
injection. Animal care and experiments were carried out according to protocols approved 
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by the Institutional Animal Care and Use Committee at Vanderbilt University. Grafts were 
paraffin-embedded, sectioned, stained with H&E, and analyzed by light microscopy. A 
tumor was defined as a palpable mass that contained carcinoma cells upon histological 
examination. Immunostaining was performed as described (Abdulkadir, 2001a; Abdulkadir, 
2001b) using anti-synaptophysin (BD Biosciences), anti-androgen receptor (Santa Cruz 
Biotechnology). 
Results 
Knockdown of Pim1 expression in MYC and Pim1 overexpressing tumor-derived cell 
lines 
In Chapter II, we demonstrated that Pim1 and MYC cooperation leads to 
advanced prostate cancer with neuroendocrine differentiation 6 weeks postgrafting. In 
this study, we isolated cells from MYC and Pim1 induced tumors and established a cell 
line named MPT, standing for MYC and Pim1 overexpressing Tumorigenic cells (Figure 
36A). These cells expressed MYC and Pim1 as they contain exogenous plasmids 
bicistronically expressing MYC or Pim1 as well as YFP (see Chapter II, Figure 17). MPT 
cells expressed neuroendocrine cell marker neuron-specific enolase (NSE), consistent 
with neuroendocrine differentiation in MYC/Pim1 tumors (Figure 36B).  To test whether 
reducing Pim1 expression impacts oncogenesis, and whether Pim1 can be a potential 
therapeutic target, we used a shRNA approach to inhibit Pim1 expression. MPT cells 
were transduced with lentiviral shRNAmir against mouse Pim1 or nonsilencing control 
(named shPim1#1 or shControl#1, respectively). To exclude off-target effects, MPT cells 
were transduced with another shRNA targeting Pim1 or control lentivirus (named 
shPim1#2, or shControl#2, respectively).  shPim1#1 targets mouse Pim1 only, while 
shPim1#2 targets both mouse and human Pim1. Stable knockdown and corresponding 
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control cells were used for the following experiments. Western blot analysis showed that 
Pim1 expression was efficiently knocked down by two sets of shRNA (Figure 36B). 
Notably, Pim1 knockdown did not change the expression level of MYC in MPT cells. 
 
 
Figure 36. Knockdown of Pim1 expression in 6-week MYC/Pim1 tumor derived cell lines. A, Left: 
Over-expression of MYC and Pim1 results in large tumors 6 weeks postgrafting in tissue recombination 
experiments. H&E staining showed the poorly differentiated tumor. Right: The image of established cell 
line from 6-week MYC/Pim1 tumor. YFP fluorescence can be seen under fluorescence microscope as the 
cells contain exogenous plasmids bicistronically expressing MYC, and Pim1 as well as YFP (Scale bar: 
100 µm). B, Left:  Western blot shows that parental MPT cells express MYC and Pim1, and neuron-
specific enolase (NSE). MPT cells were infected with lentivirus containing GIPZ shRNAmir against Pim1 
(shPim1#1) or Non-silencing-GIPZ shRNAmir (shControl#1). Western blot shows that Pim1 is knocked 
down by shPim1#1. Right: Pim1 expression was stably knocked down using pLKO.1 shRNA against Pim1 
(shPim1#2), pLKO.1 empty vector was used as control (shControl#2).  
 
We also established a second cell line, named MPT2, from a 4-week MYC/Pim1 
graft (Figure 37A). In our previous tissue recombination experiments, 4-week 
MYC/Pim1 grafts consisted of HGPIN and prostate adenocarcinomas that were androgen 
receptor (AR) positive and neuroendocrine cell marker synaptophysin negative (Chapter 
II, Figure 24).  Figure 37B showed that Pim1 was markedly knocked down in MPT2 cells. 
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MPT2 cells expressed NSE and initially expressed AR but lost it with increasing 
passages in culture. These cells also expressed NSE, suggesting that MPT2 cells might 
aquire features of neuroendocrine differentiation (Figure 37B).  
 
Figure 37. Knockdown of Pim1 expression in 4-week MYC/Pim1 tumor derived cell lines. A, An 
established cell line from 4-week MYC/Pim1-expressing tumor (named MPT2). A representative image of 
MPT2 cells in bright field (left) and under fluorescence microscopy (right) (Original magnification: 200×).  
B, Western blot shows that MPT2 cells express MYC and Pim1. Pim1 expression was stably knocked 
down in MPT2 cells using shPim1#2. MPT2 cells express androgen receptor (AR) in early passages, but 
not in late passages. NSE is also expressed in MPT2 cells.  
Pim1 knockdown impairs prostate tumor cell proliferation and survival 
Although Myc level was not changed in MPT and MPT2 cells, cell growth curves 
showed that Pim1 knockdown substantially reduced cell growth comparing to the control 
cells (Figure 38A). MTS proliferation assay also showed that knockdown of Pim1 in 
MPT and MPT2 reduced proliferation (Figure 38B). Pim1 has been implicated in anti-
apoptosis functions via interactions with the anti-apoptotic molecules, bcl-2 and Gfi-1 
(Schmidt, 1998); or phosphorylation and inactivation of Bad, FOXO3a and ASK1 (Aho, 
2004; Morishita, 2008; Gu, 2009). Under regular cell culture conditions, Pim1 
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knockdown slightly increased the rate of cell apoptosis but was not statistically 
significant (data not shown). Both MPT and MPT2 cells are serum sensitive. Both Pim1 
knockdown cells showed higher rates of apoptosis than corresponding controls, as 
determined by activated Caspase 3 staining in low serum condition (Figure 38C). These 
results suggested that Pim1 plays a role in promoting cell proliferation and protecting 
from cell death under adverse conditions. 
 
Figure 38, Pim1 knockdown of MPT cells reduced proliferation and survival. A, Growth curve is 
generated by counting shPim1#1 and shControl#1 MPT cells for 4 days, duplicated wells for each time 
points. *P<0.05. B, Cell proliferation is measured by OD 490 nm using the CellTiter 96® AQueous One 
Solution Cell Proliferation Assay (MTS, Promega). The absorbance is directly proportional to the number 
of living cells in culture. The results are mean  SD of quadruplicate wells after 3 days of incubation of 
2000 cells. *P<0.05. C, Left panel: Representative image of active caspase 3 staining (red) of overnight 
serum starved cells (0.5% serum in DMEM/F12).  Nuclei are counterstained with DAPI (blue) (Original 
magnification: 400×).  Right panel: Quantification of apoptosis rate by counting activated capase 3 positive 
cells.  The results are mean SD of two independent experiments *P<0.05.  
 
To extend our findings beyond MPT and MPT2 cell lines, we studied the effects 
of Pim1 knockdown in DU145 cells.  DU145 is a human prostate cancer cell line that has 
endogenous PIM1 and MYC expression. We used shPim1#2 that targets both human and 
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mouse Pim1 mRNA sequence to knock down PIM1 in DU145 cells. Figure 39A showed 
that PIM1 was substantially knocked down in DU145. Endogenous MYC level was also 
reduced by PIM1 knockdown. NSE was expressed by DU145 cells, consistent with the 
previous result of expression of neuroendocrine cell markers in DU145 cells (Leiblich, 
2007). NSE expression was not altered by PIM1 knockdown. PIM1 knockdown in 
DU145 cells reduced proliferation comparing to control cells as shown by MTS 
proliferation assay (Figure 39B). PIM1 prevented serum starvation-induced cell apoptosis, 
consistent with results in MPT and MPT2 cells (Figure 39C). These results indicated that 
Pim1 promotes cell proliferate and survival potential in prostate cancer cells in vitro. 
 
 
Figure 39. Pim1 knockdown of DU145 cells reduced proliferation, survival and transformation 
potential.  A, DU145 cells are transduced with shPim1#2 or shControl#2 lentivirus. Stable cell lines 
selected by puromycin were used for following experiments. Western blots show that PIM1 is knocked 
down, and MYC level is reduced upon Pim1 knockdown. DU145 cells express NSE. B, Cell proliferation is 
measured by MTS assay. The results are mean SD of quadruplicate wells after 3 days of incubation of 
4000 cells. *P<0.05. C, Quantification of apoptosis by counting active capase 3 positive cells after DU145 
cells were treated with serum free medium overnight. The results are mean SD of two independent 
experiments *P<0.05. D, Left panel: reprehensive images of soft agar assay show that Pim1 knockdown in 
DU145 cells reduce the size and number of colonies (Original magnification: 4×).  Right panel: 
Quantification of colonies from soft agar assay of Pim1 knockdown and corresponded control DU145 cells. 
The results are mean s.d. of triplicates (Colony cut-off size: 100 µm). *P<0.05. 
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Pim1 knockdown impairs prostate tumor cell tumorigenicity 
Loss of cell contact-inhibition is one of the hallmarks of cancer cells. We used a 
focus-formation assay to test whether Pim1 knockdown in MPT cells affected 
transforming ability in vitro. The results showed that control MPT cells lost contact 
inhibition and formed lots of foci, while Pim1 knockdown cells abrogated focus-forming 
ability (Figure 40A, B). Anchorage independent growth is another way to test cell 
transformational potential in vitro. We tested whether Pim1 knockdown in DU145 cells 
inhibits anchorage-independent growth using a soft agar colony formation. After 2 weeks 
growing in soft agar, Pim1 knockdown cells exhibited markedly fewer and smaller 
colonies than control cells (Figure 39D). These results indicate that Pim1 plays a role in 
maintaining transforming potential of prostate cancer cells. 
To investigate whether Pim1 knockdown can reduce tumorigenicity in vivo, Pim1 
knockdown MPT cells (shPim1#1) or control MPT cells (shControl#1) were injected 
subcutaneously in athymic nude mice and graft growth was monitored over 12 weeks 
(n=10). No apparent tumors were seen in the Pim1 knockdown group. H&E staining of 
tissue sections from the injected areas indicated that they are composed of fat, muscle, or 
lymph nodes but no tumor cells were found (Figure 40C, D, E). In contrast, the control 
group formed large tumors, resulting in 60% tumor incidence (6 out 10 sites of 
inoculation) (Figure 40C, D, E). In histology, control group consisted of sheets of tumor 
cells, and expressed neuroendocrine differentiation marker synaptophysin (SYP), but did 
not express androgen receptor (AR), E-cadherin, p63, cytokeratin 8 and smooth muscle 
actin, consistent with the features of MYC/Pim1 tumor from tissue recombination  
experiments (Figure 40F, and data not shown). These results, taken together with our 
previous data on the effects of Pim1 overexpression on prostate cell transformation (See 
68 
 
Chapter II), indicate that although Pim1 overexpression alone is not sufficient to initiate 
the development of invasive prostate cancer, continued Pim1 expression is required to 
maintain prostate cancer cell tumorigenicity. 
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Figure 40. Pim1 maintains the tumorigenic potential of MPT cells.  A, Representative images of focus 
formation assay by two independent experiments. The result shows that non-silencing control MPT cells 
(shControl#1) lose cell contact inhibition and form colonies, whereas Pim1 knockdown cells (shPim1#1) 
keep cell contact inhibition without focus-forming ability. B, Similar result as A is seen in shControl#2 and 
shPim1#2 MPT as well. C, Pim1 knockdown (shPim1#1) or non-silencing control MPT cells (shControl#1) 
were injected subcutaneously into nude mice. No tumor is found in Pim1 knockdown group. Control group 
forms large tumor after 12 weeks grafting. D, Pim1 knockdown group (shPim1#1) abrogates subcutaneous 
engraftment, as compared with a 60% tumor take in the non-silencing control group (shControl#1). 
Numbers in the parentheses indicate the number of replicates in each group. E, Representative H&E images 
of graft sections.  shControl#1 group shows high-grade tumor, consistent with features of MYC/Pim1 
tumor in tissue recombination experiments. shPim1#1 group shows fat and blood vessel cells without tumor 
cells. Scale bar: 100 µm. Insets: Higher-magnification images. F, shControl#1 grafts are synaptophysin 
(SYP) positive and androgen receptor (AR) negative. Scale bar: 100 µm. Pim1 knockdown grafts are not 
analyzed because no tumor cells are found by H&E staining. Inset: AR positive control section. 
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Pim1 knockdown impairs ERK signaling pathway activation  
An increasing number of studies have shown that multiple signaling pathways are 
activated in various human cancers. AKT/mTOR and ERK MAPK signaling pathways 
are often up-regulated during human prostate cancer progression (Abreu-Martin, 1999; 
Gioeli, 1999; Malik, 2002; Mulholland, 2006; Shen MM, 2007; Kinkade, 2008). Our 
results showed that Pim1 knockdown impaired potentials of cell proliferation, survival, 
and tumorigenicity. We want to detect whether Pim1 knockdown affects AKT/mTOR 
and ERK/MAPK signaling pathways. We first compared the level of phosphorylation of 
AKT, mTOR, S6k, PDK1 between Pim1 knockdown cells and control cells using 
Western blot analysis and results showed no distinct differences in the AKT/mTOR 
pathways (data not shown). We found that ERK1/2 phosphorylation was consistently 
reduced by Pim1 knockdown in MPT, MPT2, and DU145 cells (Figure 41A, B, C and D). 
Phosphorylation of ERK indicates activation of the MAPK pathway. Pim1 knockdown 
reduced the phosphorylation of ERK, suggesting that Pim1 is essential for MAPK 
signaling activation. We next examined whether Pim1 expression is sufficient to induce 
phosphorylated ERK. Since serum can induce ERK phosphorylation, we starved cells 
with serum free medium and tested ERK1/2 phosphorylation in Pim1 stably 
overexpressing cell lines LNCaP, PC-3, and DU145 cells (Roh, 2003; Kim, 2010). We 
found that overexpression of Pim1 did not affect ERK phosphorylation (Figure 41E, F, 
and data not shown). These results indicated that while Pim1 is necessary for activation 
of MAPK signaling, it appears that Pim1 alone is not sufficient to mediate this activation 
in vitro. We further tested the phosphorylated ERK1/2 in tissue recombination grafts by 
Western blot. Compared to the control graft, Pim1 overexpression increased ERK1/2 
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phosphorylation without affecting total ERK level (Figure 41G), indicating that MAPK 
pathway can be activated by Pim1 overexpression in vivo.  
 
Figure 41. Pim1 is essential for ERK activation.  A, B, C, D, Western blots show that Pim1 knockdown 
decreases phosphorylation of ERK1/2 compared to control. A, shPim1#1 MPT cells; B, shPim1#2 MPT 
cells; C, shPim1#2 MPT2 cells; D, shPim1#2 DU145 cells with their correspondent controls. E, F, Western 
blots showed that Pim1 overexpression did not increase phosphorylation of ERK1/2 compared to control. 
Neo, empty vector control. G, Western blot analysis of 6-week graft tissue lysates shows increased 
phosphorylation of ERK1/2 in Pim1 group compared to control.  
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Discussion  
Although Pim1 is weakly oncogenic, it synergizes dramatically with Myc to 
induce invasive prostate cancer with characteristics of neuroendocrine cancer (Chapter II, 
Wang, 2010). The basis for this synergism between Pim1 and Myc is not well understood. 
To understand the function of Pim1 on MYC/Pim1 cooperation in prostate tumorigenicity, 
we knocked down Pim1 expression in MYC/Pim1 tumor derived cell lines and a human 
prostate cancer cell line DU145. We found that, while Pim1 alone is not sufficient to 
initiate development of invasive prostate adenocarcinoma, depletion of Pim1 expression 
resulted in decreased growth rate, survival, and tumorigenic potential, suggesting that 
Pim1 is required for maintenance of the tumorigenic phenotype. In MPT cells, Pim1 
knockdown reversed their tumorigenic phenotype even when MYC level was not 
decreased, which further illustrated that Pim1 and MYC synergism in prostate cancer 
may depend on other mechanisms in addition to enhancing Myc activity and stability. In 
addition, Pim1 knockdown cells displayed reduced ERK phosphorylation. Decreased 
MAPK signaling activation may be correlated with decreased proliferation and 
tumorigenicity in Pim1 knockdown cells. These results indicate Pim1 is essential for 
MAPK signaling activation, consistent with a previous report showing that Pim1-
depleted and Pim1-inhibitor treated bone marrow cells has impaired ERK 
phosphorylation (Grundler, 2009). Our data further suggested that Pim1 overexpression 
did not enhance ERK phosphorylation in vitro, but in vivo. This is consistent with a 
report showing that MAPK signaling is activated in cardiac-specific Pim1 transgenic 
mice but is not activated in Pim1 overexpressing cardiomyocyte cultures (Muraski, 2008). 
The Raf–MEK–ERK/MAPK pathway is subject to many levels of regulation. Our data 
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and previous reports indicated that Pim1 may not directly activate ERK/MAPK signaling 
pathway (Yan, 2006; Muraski, 2008). Constitutive ERK/MAPK activation appears to 
play a critical role for NE differentiation in prostate cancer cells (Yuan, 2007). It needs to 
be further investigated whether reduced ERK/MAPK signaling activation by Pim1 
knockdown is correlated with decreased NE differentiation and tumorigenicity.  
Many studies implicate that targeting Pim1 could be a promising strategy in anti-
cancer therapy. Importantly, Pim1 depletion has only subtle effects for normal cells. 
Pim1 deficient mice are ostensibly normal, healthy and fertile (Laird, 1993). Pim1, Pim2 
and Pim3 compound knockout mice are viable and fertile, but show a profound reduction 
in body size, suggesting Pim kinases might act as sensitizers for growth factor signaling 
pathways (Mikkers, 2004). Pim kinase inhibition using SGI-1776 in prostate cancer cells 
or CLL cells (B-cell chronic lymphocytic leukemia) results in a concentration dependent 
induction of apoptosis (Mumenthale, 2009; Chen, 2009b). Prostate cancer initially 
responds to androgen ablation therapy, but eventually progresses to an androgen-
independent stage. It is still a challenge for effectively treatment of advanced hormone-
refractory prostate cancer. The aggressive malignancy of neuroendocrine tumors is 
believed to be associated with hormonal independence (Vashchenko, 2005; Abrahamsson, 
1999). In this study, we knocked down Pim1 expression in androgen independent cell 
lines and showed Pim1 knockdown abrogated tumorigenesis. Activation of MAP kinase 
signaling pathway has been implicated in advanced and androgen-independent prostate 
cancers (Gao, 2006). Pim1 knockdown reduced ERK signaling activation, suggesting a 
functional role of Pim1 in maintaining tumorigenicity. Therefore, Pim1 kinase is required 
for maintenance of a transformed phenotype, indicating that Pim1 could be an attractive 
drug target for prostate cancer treatment.   
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CHAPTER IV 
 
GENERAL DISCUSSION AND FUTURE DIRECTIONS 
 
 
Although cooperation between Pim1 and Myc was described many years ago in 
mouse lymphoma models (Verbeek, 1991; van Lohuizen, 1989; Möröy, 1991), the 
association of Pim1 and Myc in prostate cancer had not been clearly demonstrated in any 
in vivo animal models previously. In addition, it is debatable whether PIM1 is a key gene 
or a downstream player in cancer development and progression. Our study clearly 
demonstrated that Pim1 itself was a weak oncogene, but when it cooperated with MYC, 
dramatically accelerated MYC induced tumorigenicity. Further studies indicated that 
Pim1 was required to maintain tumorigenicity and ERK/MAPK signaling activity. Thus, 
Pim1 could represent a therapeutic target for treatment of prostate cancer.  
Some limitations regarding a tissue recombination model coupled with lentiviral-
mediated gene transfer  
In tissue recombination experiments, we used lentivirus to transduce adult 
prostate cells. This approach enables expression of a transgene in a few cells initially, 
which mimics the initiation of human cancer. In the current study, we used freshly 
isolated adult prostate cells and embryonic rat UGM cells in order to reduce undesired 
differentiation of the prostate stem/progenitor cells and to avoid artificial selection of cell 
population in the cell culture condition. Using this model we were able to define a role 
for Pim1 or MYC or their synergism in the development of prostate cancer. Furthermore, 
we were able to establish many cell lines from MYC/Pim1 tumors. However, there are 
some limitations in this tissue recombination model. 
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Lentivral infection is extensively used by many studies since it is very powerful to 
transduce both dividing and non-dividing cells. High MOI (Multiplicity Of Infection: the 
ratio of infectious virus particles to target cells) can increase transduction efficiency and 
transgene expression, but it can also increase the risk of insertion mutagenesis due to 
integration of multiple copies of transgene per cell (Woods, 2002; Kustikova, 2003). We 
infected cells for 3 hours using similar MOI and centrifuge method as described (Xin, 
2003). Two days post-infection, approximately 20-30% of cells were YFP positive by 
flow cytometry analysis (data not shown). Since the percentage of cells with the 
transgene expression was not very high, we did not attempt to evaluate the association of 
MOI and transgene copy numbers obtained in single cells. Although the risk of multiple 
and potentially harmful viral integrants per cell might exist due to insertional mutagenesis, 
we did not find any abnormalities in the regenerated control grafts. Further, we also 
found similar effects for multiple tissue recombination experiments. Thus, we think our 
study may not involve insertional mutagenesis.  
Another risk for lentiviral transduction is viral vector shuttle via transplanted cells 
resulting in undesired transduction of recipient cells (Blömer, 2005). In our study, mouse 
prostate cells infected by lentivirus and UGM cells are combined and incubated overnight, 
so the risk of viral vector shuttle may exist in our study. In order to test whether lentiviral 
particles in mouse prostate cells transduced into adjacent rat UGM cells, we carefully 
examined MYC expression in MYC grafts using immunohistochemical staining. The 
results showed that MYC expression was found only in epithelial cells, but not in stromal 
cells (Figure 23).  It indicates that viral shuttle might not occur in our study. If YFP 
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antibody were available to perform immunohistochemistry, it could be further confirmed 
whether other transgenes, such as Pim1, only expressed in epithelium part.  
It is still a debate whether using total prostate cells is sufficient or using isolated 
prostate epithelial cells for tissue recombination experiments. In our study, transgene 
expression could be expressed in any cell type because the lentiviral transfer vector 
contains the ubiquitin promoter (Lois, 2002), but we did not isolate epithelial cells for 
tissue recombination experiments based on the following considerations. First, tissue 
recombination requires stem/progenitor cells stimulated by the UGM cells to regenerate 
prostate glands. Current methods for isolating prostate epithelial cells are mainly based 
on the size or/and cell surface markers. Since there are no consistent standards for 
selection of stem/progenitor cells, we might lose the stem/progenitor population after the 
isolation of prostate epithelial cells.  Second, adult stromal fibroblasts could not survive 
after tissue recombination. Hoechst dye staining confirmed that the stromal cells 
observed in regenerated glands were of rat origin derived from rat UGM cells. Our data 
also showed that none of stromal cells expressed MYC transgene and MYC only 
expressed in luminal cells in the epithelium of regenerated glands. Therefore, we believe 
it is appropriate to use total prostate cells to perform tissue recombination experiments.. 
Prostate neuroendocrine cancer 
Neuroendocrine (NE) cells are rare in normal prostate epithelial compartments. 
NE differentiation increases during prostate cancer progression, which is correlated with 
aggressive disease, tumor grade, hormone deprivation therapy and survival 
(Abrahamsson, 1999; Miyoshi, 2001; Hirano, 2004; Vashchenko, 2005; Bonkhoff, 
77 
 
2005, Taplin me, 2005; Berruti, 2005; Mcwilliam; 1997; Kamiya, 2008). Although 
normal NE cells could transform to NE-like tumor cells, more evidence supports that 
adenocarcinoma cells can undergo a transdifferentiation process to become NE-like cells 
(Cindolo, 2007). Ta-Chun Yuan et al. pointed out that NE cells in prostate cancer 
originate from cancerous epithelial cells, but not from normal NE cells, and should be 
defined as ‘NE-like cancer cells’ (Yuan, 2007). They proposed that adenocarcinoma cells 
can undergo a transdifferentiation process to become NE-like cells. These NE-like cells 
acquire a similar phenotype as normal NE cells and express several NE markers, but still 
retain some epithelial characteristics (Figure 42). 
 
Figure 42. Proposed models of the cellular origins of prostate NE cancer. Model I shows that rare 
neuroendocrine cells are transformed and give rise to NE PIN, then to neuroendocrine prostate cancer. 
Model II shows that epithelial cells are transformed and give rise to PIN, adenocarcinoma, and then 
adenocarcinoma transdifferentiate to neuroendocrine prostate cancer. 
 
Our data suggests that NE carcinoma may be derived from adenocarcinoma 
(Figure 24 and 25). In addition, Gene Set Enrichment Analysis (GSEA) showed that 6-
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week MYC/Pim1 tumors or derived cell lines exhibited similar profiles of gene 
expression as human prostate cancer or cell lines but not as NE cells in normal tissues 
(data not shown), consistent with a previous report showing that NE-like tumor cells 
share identical profiles with non-NE tumor cells (Sauer, 2006). The mechanism of 
transdifferentiation of prostate cancer into NE-like tumor is unknown. Both TRAMP and 
Rb/p53-null mice show simultaneous inactivation or knockout of both p53 and Rb genes, 
which promotes NE like prostate cancer (Perez-Stable, 1997; Zhou, 2006). It has been 
reported that IL-6 signaling induces neuroendocrine differentiation (Palmer, 2005). 
ERK/MAPK activation was reported to be a potential mechanism in this 
transdifferentiation and may serve as a therapeutic target (Yuan, 2007). Proper animal 
models and cell lines are needed to elucidate the molecular basis of NE differentiation. 
However, it is claimed that “virtually no animal models of a neuroendocrine/small cell 
variant of prostate carcinoma are available for experimental studies” (Yuan, 2007). Given 
that there is limited research on NE tumor, MYC/Pim1 tumors and/or derivative cell lines 
could be valuable tools for studying the molecular mechanisms for NE 
transdifferentiation, and for developing and evaluating therapies for NE tumor.  
Prostate cancer develops from normal prostate to PIN to adenocarcinoma, and 
then transits to NE-like cancer, finally to metastasis. We have observed this progression 
in the Pim1 and MYC tissue recombination model (Table 2). Therefore, our tissue 
recombination would provide valuable information for the mechanisms of prostate cancer 
progression, and for developing novel diagnosis and therapeutic approach. 
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Table 2.  The progression of prostate cancer is demonstrated by histology of regenerated grafts  
 
 
 
 
 
Clinical significance of MYC/PIM1 synergism in human prostate cancer  
A major clinical problem is the development of castration-resistant prostate 
cancer (CRPC) during androgen ablation treatment. The molecular mechanisms 
underlying the change from androgen dependence to castration-resistance are not well 
understood and represent a challenge for development of efficient therapies.  It has been 
suggested that Myc may be involved in development of CRPC (Bernard, 2003). On the 
other hand, Pim1 enhances cell survival at castrate levels of androgen and 
neuroendocrine functions of PC12 cells (Glazova, 2005). Coexpression of MYC and 
PIM1 was frequently found in patients under androgen ablation therapy (van der Poel, 
2010). In this study, we found that coexpression of MYC and PIM1 is associated with 
high Gleason grade in human prostate tumors. Using a mouse tissue recombination model 
we demonstrated that Pim1 strongly cooperates with MYC, resulting in advanced prostate 
cancer with NE differentiation. NE tumors are correlated with hormonal independence 
(Vashchenko, 2005; Abrahamsson, 1999). Therefore, our tissue recombination model and 
its derivative cell lines could be extensively used for evaluation of the mechanisms of 
CRPC. It remains to be determined whether coexpression of MYC and PIM1 is 
Phenotype Weeks Name 
Benign 
 
6 Control 
6 Pim1 
PIN 6 MYC 
12 Pim1 
Adenocarcinoma 
 
4 MYC/Pim1 
12 MYC 
NE-like carcinoma 6 MYC/Pim1 
12 MYC 
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associated with neuroendcrine cancer in patients. Of importance in clinic is the need to 
know if coexpression of MYC and PIM1 can be used for distinguishing indolent versus 
aggressive prostate cancer. 
Potential cancer stem cells in MYC/Pim1 tumors 
Takahashi and Yamanaka reported that four transcription factors (Oct4, Sox2, 
Klf4, and c-Myc) can reprogram mouse and human somatic cells to be pluripotent 
(Takahashi, 2006). MYC contributes to cancer initiation and progression by stimulating 
an embryonic stem cell-like signature characterized by an enrichment of genes involved 
in ribosome biogenesis and by repressing differentiation (Koh, 2010). It is of interest to 
know whether synergism of Pim1 and MYC enhances stem /progenitor cell-like 
characteristics. 
MYC/Pim1 induced tumor shows evidence of neuroendocrine (NE) 
differentiation, which arises by transdifferentiation of adenocarcinoma cells with 
progression. This indicates that MYC/Pim1 tumors have plasticity within a specific time 
range. At 6 weeks, although the majority of MYC/Pim1 tumor had lost Nkx3.1 
expression, there were a few Nkx3.1 positive cells scattered in the tumor (Figure 43). It 
remains to be determined whether those Nkx3.1 positive cells represent cancer stem cells 
like CARNs (Wang, 2009). We also studied AR expression in the adenocarcinoma part of 
MYC/Pim1 tumor (Figure 44). Of note, a small amount of cells did not express AR in 
those parts. Since there is debate over AR status in prostate stem cells (Shen, 2010), it 
needs to be determined whether these cells have cancer stem cell properties. It also 
remains to be studied whether Nkx3.1 positive cells are those AR negative cells in 
MYC/Pim1 tumor. Furthermore, double staining of stem cell markers (for example Sca-1 
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Sca-1, CD133, CD117, CD44) and cell lineage markers (for example CK5, CK8, 
synaptophysin) may facilitate the identification of the cell origin of cancer stem cells in 
MYC/Pim1 tumors. 
 
Figure 43. A few areas of MYC/Pim1 tumor section showing Nkx3.1 expression. Immunohistochemical 
staining shows common loss of Nkx3.1 expression in MYC/Pim1 tumors (left), Nkx3.1 positive cells are 
seen in a few areas (middle and right) (Original magnification: 400×).. 
 
 
Figure 44. Early loss of AR expression in MYC/Pim1 tumors. Immunohistochemical staining shows 
some AR negative cells in the early lesions of MYC/Pim1 tumors (Original magnification: 400×). 
 
A sphere forming assay has been developed to study the function of stem cells in 
vitro (Xin, 2007; Garraway, 2010). Our preliminary data showed that earlier passages of 
control MPT cells were able to form a lot of spheres, while Pim1 knockdown 
dramatically decreased the number of sphere forming cells (Figure 45). Late passages of 
MPT cells lost the sphere forming proprieties for unknown reasons. It remains to be 
determined whether these spheres enrich a stem cell/progenitor population. We have 
other early passages of MYC/Pim1 cells that may help us further characterize these 
spheres. 
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Figure 45, Control MPT cells form more spheres than Pim1 knockdown cells. Upper panel: 
Representative images of solid spheres in Matrigel show that control MPT cells (shControl#1) are enriched 
for sphere-forming cells, which Pim1 knockdown cells (shPim1#1) lose this potential (Original 
magnification: 100×).  Lower panel: Graph shows the numbers of spheres. Results represent the mean + SD 
of triplicate wells after 7 days of incubation. 
 
Potential conjunction of PIM1 kinase and ERK inhibitors in the treatment of 
prostate cancer 
Cancer is a multistep process including activation of proto-oncogenes and 
inactivation of tumor suppressor genes. Extensive evidence shows that inactivation of a 
single oncogene can be sufficient to induce sustained tumor regression. These 
observations brought about oncogene addition concept which emphasizes the dependency 
of some cancers on one or a few genes for the maintenance of the malignant phenotype 
(Weinstein, 2006).  
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Oncogene addition has been shown in Myc transgenic mice (Felsher, 1999; 
Pelengaris, 2002). Targeting Myc could be an effective target in cancer therapy, but may 
be harmful for normal cells since it is a very important transcription factor for a living 
cell. Loss of Pim1 expression has only subtle effects in mice (Laird, 1993). In this 
scenario, we are interested in Pim1 inhibition in prostate cancer treatment. We speculated 
that Pim1 may establish a preneoplastic state although its overexpression is not sufficient 
to initiate prostate adenocarcinoma. Since Pim1 alone cannot induce tumorigenesis and 
there are examples of escaping from oncogene addiction (Ewald, 1996; Plattner, 1996), it 
remains to be determined whether inactivation of Pim1 is sufficient to induce prostate 
tumor regression. If Pim1 is not necessary to maintain tumorigenicity, Pim1 inhibitor 
might not be effective for cancer treatment. Thus, the results of our research are 
important in light of recent efforts in the development of Pim1 kinase inhibitors. In the 
current study, we found that depletion of Pim1 expression in established prostate cancer 
cell lines resulted in reduced cell proliferation, survival and tumorigenicity, indicating 
that Pim1 is required for tumorigenic maintenance. Because Pim2, Pim3 or other genes 
can compensate for Pim1 deficiency (Berns, 1999), it remains to be seen whether long-
term inhibition of Pim1 leads to a compensatory up-regulation of other PIM family 
members. 
The PIM1 kinase inhibitor quercetagetin is able to inhibit PIM1 activity in 
prostate cancer cells in a dose dependent fashion (Holder, 2007). In our preliminary study, 
we also found that Pim kinase inhibition using quercetagetin resulted in dose dependent 
reduction of MPT cell viability (Figure 46).  
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Figure 46. Pim1 inhibitor quercetagetin decreases MPT cell viability. MPT cells are treated with 
different doses of quercetagetin and cell viability is tested using CellTiter-Glo Luminescence Cell Viability 
Assay (Promega). 
 
The MYC/Pim1 cancer model may highly appropriate to test the efficacy of Pim1 
inhibitors in vivo. 4-week MYC/Pim1 grafts displayed HGPIN and adenocarcinoma, 
while 6-week MYC/Pim1 formed neuroendocrine tumor. It is of interest to determine 
whether Pim1 inhibitor, such as SGI-1776, is able to abrogate MYC/Pim1 tumorigenicity 
6 weeks post-grafting, and to prevent 4-week MYC/Pim1 early lesions progressing to 
neuroendocrine tumor at 6 weeks using tissue recombination approach. 
At present, effective treatment for advanced cancers is still a significant challenge. 
ERK/MAPK signaling is frequently activated in prostate cancer, especially in advanced 
cancer and CRPC (Abreu-Martin, 1999; Gioeli, 1999; Mailik, 2002). Pim1 
overexpression has been found in prostate cancer and associated with high grade tumor 
(Dhanasekaran, 2001; Valdman, 2004; Cibull, 2006; van der Poel, 2010). In addition, 
Pim1 plays an important role in multidrug resistance (Xie, 2006; 2008). Inhibiting Pim1 
0
20
40
60
80
100
120
0 µM 1 µM 10 µM 25 µM
Quercetagetin concentration
R
el
at
iv
e 
vi
ab
ili
ty
 (%
)
85 
 
expression increases the sensitivity of prostate cancer cells to specific chemotherapy 
(Mumenthale, 2009). Therefore, adjunctive use of Pim1 and ERK inhibitors is expected 
to increase apoptosis, improve the efficacy and lower drug dosages. This combination 
therapy is also expected to lower the cytotoxicity and enhance tumor suppression in vivo, 
which would be important in treating hormone-refractory prostate cancer. 
Possible mechanisms of Pim1 and Myc cooperation 
Pim1 enhances Myc stability and activity  
The MYC and Pim1 oncogenes are frequently overexpressed in prostate cancer, 
and together they are sufficient to induce advanced prostate cancer in a mouse model. 
The precise mechanism of Pim1 as such an effective partner of Myc in tumorigenicity 
remains obscure. In vitro studies have shown that Pim1 promotes Myc induced 
tumorigenicity by increasing Myc stability through decreasing PP2A activity (Chen, 
2005), through increasing Myc S62 phosphorylation and decreasing T58 phosphorylation 
(Zhang, 2008), or by increasing Myc transcriptional activity through phosphorylation of 
histone H3 at Myc target genes (Zippo, 2007, Figure 47).  
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Figure 47. Summary of possibilities regarding Pim1 and Myc cooperation. Solid arrows show 
published findings; broken arrows show potential interactions with ERK/MAPK pathway (see the text for 
details and references). 
 
It is well known that phosphorylation of N terminal threonine 58 (T58) and serine 
62 (S62) has been implicated in regulating stability of MYC. First, S62 can be 
phosphorylated by ERK, and then T58 is phosphorylated by glycogen synthase kinase-3β 
(GSK-3β).  Double phosphorylated MYC is isomerized by Pin prolyl isomerase and S62 
is then dephosphorylated by serine/threonine protein phosphatase 2A (PP2A), which 
drives polyubiquitination and proteasomal degradation of MYC (Figure 48) (Sears, 2004).  
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Figure 48. Phosphorylation of N terminal threonine 58 (T58) and serine 62 (S62) regulates Myc 
turnover (See text for details). 
 
In MYC/Pim1 tumors, both MYC and Pim1 proteins levels appeared elevated 
compared to Pim1 alone or MYC alone grafts (Figure 18C and 34A). This is likely 
because both MYC and Pim1 were stabilized. These tumors also showed relatively 
increased Myc serine 62 phosphorylation, which is claimed to be a stabilized and activate 
form (Sears, 2004). Whether or how Pim1 stabilizes MYC or vice versa needs to be 
explored in the future study.  
In chapter II, we found Pim1 greatly accelerated MYC induced prostate cancer 
progression to neuroendcrine tumor within 6 weeks (Figure 19, 20). MYC grafts showed 
HGPIN, but over time (12 weeks) developed adenocarcinoma with neuroendocrine 
differentiation (Figure 19, 28). In addition, weak Pim1 expression was observed in 12-
week MYC tumors with neuroendocrine differentiation (Figure 31). In summary, MYC 
stability and activity seems to be enhanced when MYC and Pim1 are over-expressed 
concurrently.  
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Although MYC/Pim1 tumors showed increased levels of MYC phosphorylation 
on serine-62, grafts expressing a phospho-mimicking MYCS62D mutant did not form 
tumors resembling MYC/Pim1 grafts, revealing that S62 phosphorylation may not be a 
crucial step for MYC/Pim1 synergism (Figure 35). In addition, MYCS62D mutant is 
supposed to be more stable than wild-type MYC, but this still needs to be validated. The 
Myc phosphorylation deficient mutants T58A has been observed in lymphomas and is 
associated with increased MYC stability (Sears, 2004; Thibodeaux, 2009). Furthermore, 
the phospomimetic mutant MYC S329D has comparable tumorigenicity as co-expression 
of PIM1 kinases and MYC in vitro (Zhang, 2008). It remains to be determined if these 
mutants with increased MYC stability, for example, T58A, or S329D, can mimic 
MYC/Pim1 synergism in vivo.  
Pim1 seems to enhance MYC functions, showing that higher gene expression of 
phosphorylated MYCS62 and MYC targets, Cyclin D1, D2, E, in MYC/Pim1 tumors 
compared to MYC alone and MYC/K67M (Figure 34). However, it is difficult to separate 
the direct effects of MYC and Pim1 expression on these target genes from indirect gene 
activation as a consequence of tumorigenesis. Examination of MYC target genes after a 
few days of introducing transgenes by lentviral infection may clarify whether Pim1 
amplifies MYC function.  
In chapter III, we showed that Pim1 knockdown abrogated tumorigenicity of 
MPT cells even when MYC level was not decreased (Figure 40), which also suggests that 
Pim1 and MYC synergism in prostate cancer may depend on additional mechanisms 
other than enhancing MYC activity and stability. 
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ERK/MAPK signaling activation may be involved in Myc and Pim1 synergism 
In chapter III, we showed that knockdown of Pim1 expression in MYC/Pim1 
derived cell lines decreased phosphorylation of ERK (Figure 41), revealing that Pim1 
plays a role in ERK/MAPK signaling activation. Interestingly, Pim1 grafts showed 
increased phosphorylated ERK comparing to control grafts (Figure 41G), but Pim1 
overexpressing cancer cell lines did not show alteration of phosphorylated ERK (Figure 
41E, F). It is still unclear whether Pim1 directly or indirectly phosphorylates ERK. In the 
primary mitogen regulated pathway, extracellular stimuli activate Raf-1, which 
phosphorylates and activates MAPK kinase (MEK), leading to the phosphorylation and 
activation of the extracellular signal regulated kinases (ERK). Activated ERK 
translocates to the nucleus and activates gene expression by phosphorylation of a series 
of substrates including MYC S62. It remains to be determined whether Pim1 affects Raf-
1 or MEK phosphorylation, or interacts with other proteins that are involved in this 
pathway (Figure 47).  
It has been reported that Pim1-deficient bone marrow expresses less chemokine 
receptor CXCR4 and shows defects in homing and migration because of impaired 
CXCL12–CXCR4 signaling (Grundler, 2009).  CXCL12 is also known as SDF1 (stromal 
cell derived factor 1), which is the predominant ligand for CXCR4. The CXCL12–
CXCR4 pathway has been implicated in promoting prostate cancer cell migration, 
invasion, angiogenesis and metastasis (Chinni, 2006; Arya, 2004; Singh, 2004; Taichman, 
2002; Xing, 2008). ERK/MAPK can be activated by CXCL12–CXCR4 signaling (Tan, 
2008, Teicher, 2010). Therefore, we speculate that Pim1 may enhance CXCR4 
expression, which interacts with CXCL12 expressed by stomal fibroblast or other cell 
type in microenvironment, leading to enhanced CXCL12–CXCR4 signaling, and thereby 
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enhancing phosphorylation of ERK. This may explain why we observed that Pim1 
increased phosphorylation of ERK in vivo, not in vitro, and why Pim1 knockdown 
decreased phosphorylation of ERK. ERK/MAPK activation can phosphorylate Myc on 
S62, thereby stabilizing Myc (Figure 48).  
Interestingly, our Gene Set Enrichment Analysis (GSEA) of microarray data 
showed that epithelial-mesenchymal transition (EMT gene) set was down-regulated in 
Pim1 knockdown cells comparing to control, while EMT gene set was up-regulated in 
MYC/Pim1 tumor (data not shown). It suggests that Pim1 may play a role in EMT. It is 
known that MAPK signaling is required for EMT in vivo and metastasis (Janda, 2002). A 
recent report shows that Pim1 promotes cancer cell migration and invasion possibly 
through a Pim1 substrate NFATc (Santio, 2010). It is important to be confirmed whether 
Pim1 involved in EMT and differentiation, which may facilitate to study on the 
mechanisms of Pim1 and Myc cooperation in tumorigenesis. 
Other potential mechanisms of Pim1 and Myc cooperation 
Using a tissue recombination approach, we found that Pim1 expression resulted in 
mild pathological abnormalities, suggesting that Pim1 overexpression may establish a 
preneoplastic state. A recent report showed that Pim1 is induced by DNA damage 
possibly mediated by the nuclear factor kappa beta (NF-κB) pathway. In addition, Pim1 
overexpressing cell lines displayed genomic instability (Roh, 2003; 2005; 2008; 
Zemskova, 2010). Whether and how Pim1 overexpression induces genomic instability 
needs be to explored in vivo. It will be of interest to know whether Pim1 and MYC 
cooperate to induce genomic instability.  
91 
 
It is well known that Myc plays an important role in promoting proliferation and 
apoptosis. Pim1 increases cell proliferation and inhibits apoptosis. Pim1 may disrupt Myc 
induced apoptotic pathways and cooperate with Myc to transform normal cells. Our 
microarray data and previous reports implicate that Pim1 and Myc may synergize in 
promoting cell cycle, possible by activating cdc25 (Mochizuki T, 1999; Bachmann., 2004; 
Galaktionov, 1996). Pim1 can induce p53-dependent senescence (Hogan, 2008; 
Zemskova, 2010). Moreover, Myc can induce senescence, which is suppressed by 
Werner syndrome protein or cdk2 (Campaner, 2010).  It needs to be investigated whether 
and how Myc and Pim1 together can bypass senescence.  
Our conventional analysis of microarray data has shown only subtle differential 
gene expression between Pim1 grafts and control grafts, and between Pim1 knockdown 
and control MPT cells (data not shown), suggesting that the synergism of Pim1 and MYC 
may be mediated by epigenetic or/and microRNA regulation.  
The major aim of our studies is to establish a mechanistic model for the 
cooperation between Myc and Pim1. As described, MYC/Pim1 synergy is critically 
dependent on Pim1 kinase activity. Of importance is the need to know what Pim1’s 
substrates are responsible for its cooperation with Myc, and what downstream targets of 
Pim1 and Myc are responsible for this cooperation. Those studies will help us better 
understanding of the molecular basis of human prostate cancer initiation and progression. 
Such studies could facilitate to development of novel methods for diagnosis and 
treatment in human cancer. 
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